0The BEST Trial: Biomarkers for Evaluating Spi[INVESTIGATOR_580484]: 00057948 
National Clinical Trial (NCT) Identified Number : [STUDY_ID_REMOVED] 
Protocol Co-Chairs:  
Daniel Clauw, MD ; Gwendolyn Sowa, MD, PhD   
Matthew Mauck, MD, PhD; Kevin Anstrom , PhD  
Sponsor: The Helpi[INVESTIGATOR_200608] -termSM Initiative (NIH HEAL 
InitiativeSM) 
Funded by : [CONTACT_167656] 
(NIAMS)  
Version Number:  7 .0 
Version Date:    September 1, [ADDRESS_763312] Trial Protocol v 7.0 ii 9/1/2023  Table of Contents  
1. SUMMARY OF CHANGES FROM PREVIOUS VERSIONS ................................................... 1  
2. STATEMENT OF COMPLIANCE  ................................................................................................. 9  
3. PROTOCOL CHAIRS AND KEY PERSONNEL  ...................................................................... 10 
4. PROTOCOL SUMMARY  ............................................................................................................... 1  
4.1. Synopsis  ................................................................................................................................. 1  
4.2. Schema  ................................................................................................................................... 6  
4.3. Schedule of Activities (SoA) ................................................................................................ 7  
5. INTRODUCTION  ............................................................................................................................ 7  
5.1. Study Background and Rationale ....................................................................................... 7  
5.2. Risk/Benefit Assessment ..................................................................................................... 8  
5.2.1. Known Potential Risks  ........................................................................................ 8  
5.2.2. Known Potential Benefits  ................................................................................. 10 
5.2.3. Assessment and Mitigation of Potential Risks  .............................................. 11 
5.2.4. Risk/Benefit Justification  .................................................................................. 14 
6. OBJECTIVES AND ENDPOINTS  .............................................................................................. 14 
7. STUDY DESIGN  ........................................................................................................................... 16 
7.1. Overall Design ..................................................................................................................... 16 
7.2. Scientific Rationale for Study Design ............................................................................... 18 
7.3. Justification for Dose/Intervention Regimens  ................................................................. 19 
7.4. End of Study Definition ....................................................................................................... 19 
8. STUDY POPULATION  ................................................................................................................. 19 
8.1. Study Inclusion Criteria  ...................................................................................................... 19 
8.2. Study Exclusion Criteria  ..................................................................................................... 19 
8.3. Study Intervention Contraindications  ............................................................................... 20 
8.4. Phenotypi[INVESTIGATOR_580485]  ......................................................................................... 21 
8.5. Lifestyle Considerations  ..................................................................................................... 22 
8.6. Screen Failures  ................................................................................................................... 22 
8.7. Str
ategies for Recruitment and Retention  ....................................................................... 22 
9. PHENOTYPIC ASSESSMENTS  ................................................................................................ 23 
9.1. Questionnaires  .................................................................................................................... 24 
9.2. Blood Draw / Venipuncture ................................................................................................ 24 
9.3. Stool Collection .................................................................................................................... 24 
9.4. Biomechanical Assessment  .............................................................................................. 24 
9.5. Imaging ................................................................................................................................. 25 
9.6. Quantitativ e Sensory Testing  ............................................................................................ 26 
10. STUDY INTERVENTIONS  .......................................................................................................... 27 
10.1. Study Intervention(s) Administration: Acceptance Commitment Therapy .................. 27 
10.1.1. Study Intervention Description  ........................................................................ 27 
10.1.2. Dosing and Administration ............................................................................... 28 
10.1.3. Acquisition and Accountability  ......................................................................... 29 
10.1.4. Study Intervention Compliance  ....................................................................... 29 
10.2. Study Intervention(s) Administration: Duloxetine ........................................................... [ADDRESS_763313] Trial Protocol v 7.0 iii 9/1/2023  10.2.6. Study Intervention Compliance  ....................................................................... 32 
10.3. Study Intervention(s) Administration: Enhanced Self-Care  .......................................... 33 
10.3.1. Dosing and Administration ............................................................................... 33 
10.3.2. Acquisition and Accountability  ......................................................................... 35 
10.3.3. Study Intervention Compliance  ....................................................................... 35 
10.4. Study Intervention(s) Administration: Evidence-Based Exercise and Manual 
Therapy  35 
10.4.1. Dosing and Administration ............................................................................... 36 
10.4.2. Acquisition and Accountability  ......................................................................... 37 
10.4.3. Study Intervention Compliance  ....................................................................... 37 
10.4.4. Measures to Minimize Bias: Randomization and Blinding .......................... 37 
11. STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL ................................................................................................... 39 
11.1. Discontinuation of Study Intervention .............................................................................. 39 
11.2. Participant Discontinuation/Withdrawal from the Study  ................................................ [ADDRESS_763314] to Follow -Up ................................................................................................................ 40 
12. STUDY ASSESSMENTS AND PROCEDURES ...................................................................... 40 
12.1. Efficacy Assessments  ........................................................................................................ 40 
12.2. Safety Assessments  ........................................................................................................... 41 
12.3.  Adverse Events and Serious Adverse Events  ................................................................ 41 
12.3.1. Definition of Adverse Events (AE)  .................................................................. 42 
12.3.2. Definition of Serious Adverse Events (SAE)  ................................................. 42 
12.3.3. Classification of an Adverse Event ................................................................. 42 
12.3.4. Time Period and Frequency for Event Assessment and Fol low-Up ......... 43 
12.3.5. Adverse Event Reporting ................................................................................. 44 
12.3.6. Reporting Events to Participants  .................................................................... 44 
12.4. Unanticipated Problems  ..................................................................................................... 45 
12.4.1. Definition of Unanticipated Problems (UP)  .................................................... 45 
12.4.2. Unanticipated Problem Reporting  ................................................................... 45 
13. STATISTICAL CONSIDERATIONS  ........................................................................................... 45 
13.1. Stati
stical Hypotheses  ........................................................................................................ 45 
13.2. Sample Size Determination ............................................................................................... 47 
13.3. Populations for Analyses  ................................................................................................... 50 
13.4. Statistical Analyses  ............................................................................................................. 50 
13.4.1. General Approach ............................................................................................. 50 
13.4.2. Analysis of the Primary Efficacy Endpoint(s)  ................................................ 51 
13.4.3. Analysis of the Secondary Endpoint(s)  .......................................................... 51 
13.4.4. Safety Analyses  ................................................................................................. 51 
13.4.5. Baseline Descriptive Statistics  ........................................................................ 51 
13.4.6. Planned Interim Analyses  ................................................................................ 51 
13.4.7. Sub-Group Analyses ......................................................................................... 51 
13.4.8. Tabulation of Individual Participant Data ....................................................... 51 
13.4.9. Exploratory Analyses  ........................................................................................ 51 
14. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  .............. 52 
14.1. Regulatory, Ethical, and Study Oversight Considerations  ............................................ 52 
14.1.1. Informed Consent Process  .............................................................................. 52 
14.1.2. Consent/assent and Other Informational Documents Provided to 
Participants  [ADDRESS_763315] Trial Protocol v 7.0 iv 9/1/[ADDRESS_763316] Policy  ................................................................................. 62 
14.2. Abbreviations  ....................................................................................................................... 63 
15. REFERENCES  .............................................................................................................................. 65 
16. SURVEY QUESTIONNAIRES  .................................................................................................... 70 
17. Appendix A:  Schedule of Activities  ........................................................................................... [ADDRESS_763317] Trial Protocol v 7.0 1 9/1/2023  1. SUMMARY OF CHANGES FROM PREVIOUS VERSIONS  
 
Version  Date of 
Revision  Section(s)  Summary of Revisions Made  Rationale  
2.0 4/20/2022  Title Page  Added document title    
2.0 4/20/2022  Title Page  Revised protocol chair names  Kevin Anstrom replaced 
Matt Psioda April 2022  
2.0 4/20/2022  Title Page  Added protocol number    
2.0 4/20/[ADDRESS_763318] Manager  
2.0 4/20/[ADDRESS_763319] mention    
2.0 4/20/[ZIP_CODE]  4.1 Objectives clarified  Per 2/11/[ADDRESS_763320]  
2.0 4/20/[ADDRESS_763321] 
intervention protocol changes , number of sites,  
and revised study launch  2.0 4/20/2022  4.1 Revised EBEM section  
2.0 4/20/2022  4.1 Revised study length  
2.0 4/20/2022  4.2 Revised schema  Corrected timing of screening call 
2.0 4/20/2022  4.3 Updated Schedule of Activities    
2.0 4/20/2022  5.2  Added duloxetine exclusion 
criteria to  risk language    
2.0 4/20/2022  5.2 Clarified and corrected risk language    
2.0 4/20/2022  8.1-8.4 Updated inclusion/exclusion 
criteria and contraindications    
2.0 4/20/2022  8.7 Revised recruitment strategies  Revised to account for site -
specific restrictions  
2.0 4/20/2022  9.2 Updated blood draw protocol    
2.0 4/20/2022  9.5 Updated imaging protocol    
2.0 4/20/2022  10.2  Updated duloxetine protocol    
2.0 4/20/2022  10.4  Updated EBEM protocol    
2.0 4/20/2022  10.5 Updated randomization 
methods    
2.0 4/20/[ADDRESS_763322] Trial Protocol v 7.0 2 9/1/2023  Version  Date of 
Revision  Section(s)  Summary of Revisions Made  Rationale  
2.0 4/20/2022  12.3 Clarified and corrected AE, 
SAE, and UP definitions and 
reporting requirements Per 2/11/[ADDRESS_763323]  
2.0 4/20/2022  13 Clarified statistical methods    
2.0 4/20/2022  14.1 Corrected safe ty oversight 
language  Per 2/11/[ADDRESS_763324]  
2.0 4/20/2022  14.1  Added data security language    
2.0 4/20/2022  14.2  Removed unnecessary listings  Per 2/11/[ADDRESS_763325]  
2.0 4/26/2022  All Revised “investigational drug 
pharmacy” to “approved pharmacy”  Not all sites will utilize Investigational Drug Services 
2.0 4/26/2022  10.2 Revised unused pi[INVESTIGATOR_580486]-person returns only   
3.0 5/27/2022  Title Page  Added National Clinical Trial 
(NCT) Identified Number  NCT Record created  
3.0 6/7/[ADDRESS_763326] Lead Biostatician   
3.0 6/6/2022  5.2.1  Added “MRS of the spi[INVESTIGATOR_050]” to 
description of additional 
imaging procedures a subset 
of participants may undergo  Increased clarity 
3.0 6/6/2022  8.3 Clarified EBEM intervention contraindications  Split two contraindications previously combined into one bullet into 2 bullets  
3.0 6/3/2022  8.4 Revised Imaging Phenotypi[INVESTIGATOR_580487]  
3.0 6/3/[ADDRESS_763327]  
3.0 6/6/2022  9 Changed “more 
comprehensive spin MRI” to The additional/deep 
phenotypi[INVESTIGATOR_580488] v 7.0 3 9/1/2023  “spi[INVESTIGATOR_580489]” and removed 
“longer than the required 
MRI” from the duration 
description  now only consists of the 
spi[INVESTIGATOR_580489]  
 3.0 5/27/[ADDRESS_763328] of blood tubes 
collected and which blood 
samples are stored for possible 
future analyses  Corrected errors  
3.0 6/6/2022  9.5 Changed “additional MRI scans of their spi[INVESTIGATOR_050]” to “a MRS scan 
of their spi[INVESTIGATOR_050]”  The additional/deep 
phenotypi[INVESTIGATOR_580490]  
3.0 6/7/2022  13.3 Added Safety Population and 
Modified Intention to 
Treatment Population   
 3.0 5/27/2022  14.1.10  Added information about 
Magnetic Resonance Imaging 
(MRI) Quality Control  Added extra measures 
taken to ensure QC of MRI 
data  
4.0 6/30/2022  4.1, 6, 7.1, 
7.2, 13.1 Clarified language throughout 
regarding the primary 
outcome of the trial.  Clarification from statistical team  
4.0 6/30/2022  4.1, 5.1, 7.1 Updated ordering of 
interventions  Clarification from statistical 
team  
4.0 6/28/2022  4.1, 10.3, 
10.3.1  Corrected duration of ESC 
intervention  Correction from ESC team  
4.0 6/28/2022  4.1, 10.3 Changed information about 
texts and emails received 
during ESC intervention  Correction from ESC team  
4.0 6/30/2022  7.1, 10.5, 
13.2 Clarified that sample size 
simulations yield approximate 
results  Clarification from statistical 
team  
4.0 7/5/2022  8.3 Added breastfeeding as a 
contraindication for the 
duloxetine intervention  ELC decision 7/6/2022  
4.0 6/28/2022  10.3 Added information about 
Walking Program module in 
PainGuide  Correction from ESC team  
4.0 6/28/2022  10.3.1 Removed information about 
ESC intervention summary 
module  Correction from ESC team  
4.0 6/28/2022  10.3.1 Updated information about 
FitBit step monitoring  Correction from ESC team  
4.0 6/28/2022  10.3.1 Updated numbering of ESC 
modules  Correction from ESC team  
4.0 6/30/2022  10.5 Minimization covariates are 
binary yes/no  Clarification from statistical 
team  
 
BEST Trial Protocol v 7.0 4 9/1/2023  4.0 6/30/2022  13.3 Updated analysis populations  Clarification from statistical 
team  
4.0 6/13/2022  14.1.10 Changed information about 
Magnetic Resonance Imaging 
(MRI) Quality Control  of Brain 
Images  Planned human scan is not 
required to  occur prior to 
scanning research 
participants  
4.0 7/22/2022  5.2.1  Corrected language used and 
timeline specified in  Risks 
Associated with Confidential 
Information Disclosure   
4.0 7/22/2022  9.2 Updated batch shippi[INVESTIGATOR_580491]   
4.0 7/22/2022  6 Corrected randomization visits 
specified in description of secondary objectives   
4.0 8/1/[ADDRESS_763329] scans   
4.0 8/8/2022  9.6 Updated information about 
Temporal Summation and Conditioned Pain Modulation 
tests   
4.0 9/12/2022  9 Corrected time needed for 
required phenotypi[INVESTIGATOR_580492]  
4.0 9/12/2022  5.2.1 , 8.4, 
9, 9.5 Changed “a MRS scan of their 
spi[INVESTIGATOR_050]” back to “advanced MRI 
scans of their spi[INVESTIGATOR_050] ” Imaging team has decided 
to revert to “advanced 
spi[INVESTIGATOR_25342]’ terminology  
4.0 9/13/2022  8.2 Updated exclusion criterion 
related to autoimmune disorders (increased specificity)  ELC decision 9/13/2022  
4.0 9/28/2022  4.2 Corrected timing of Screening 
Call 2 indicated in Schema   
4.0 10/6/[ADDRESS_763330] 
time between visits   
4.0 10/6/2022  10.2.4 Clarified language regarding 
study drug shipments   
4.0 10/6/2022  4.1, 7.4  Corrected study duration   
4.0 10/7/2022  6.0 Corrected visit #  of follow -up 
visit  
4.0 10/7/2022  8.1 Revised Run -In eligibility 
requirement to allow more 
time to watch videos and to ELC decision 10/5/[ADDRESS_763331] Trial Protocol v 7.0 5 9/1/2023  reduce the # of required 
response to the daily pain 
questions  
4.0 10/7/[ADDRESS_763332]   
4.0 10/12/2022  9.4 Clarified language regarding 
additional biomechanical 
assessments   
4.0 10/12/2022  9.5  Corrected and clarified 
imaging data flow   
4.0 10/12/[ADDRESS_763333] 
appointments   
4.0 10/12/[ADDRESS_763334] citation   
4.0 10/12/[ADDRESS_763335] language 
regarding duloxetine non -
compliance   
4.0 10/12/2022  10.4.1 Clarified number of EBEM 
visits and expectations regarding the frequency of 
EBEM fidelity assessments   
4.0 10/12/[ADDRESS_763336] to 
Follow-Up   
4.0 10/12/[ADDRESS_763337] information 
regarding tapering duloxetine   
4.0 10/12/2022  14.1.10 Corrected timing of 
harmonization scans  ECL decision  
4.0 10/12/2022  14.1.14 Defined order of phenotypi[INVESTIGATOR_580493]   
4.0 10/17/[ADDRESS_763338] the 
physical assessments   
4.0 10/20/22  5.2.1, 5.2.3, 
8.4, 9, 9.5, 
14.1.14  Removed clinical spi[INVESTIGATOR_050] x -ray 
from phenotypi[INVESTIGATOR_580494]/clinicians 
decision 
4.0 10/20/22  9 Changed duration of required 
phenotypi[INVESTIGATOR_580495] 3 to 5 hours   
4.0 10/20/22  9 Table: changed motion 
assessment to 20 minutes and changed basic spi[INVESTIGATOR_580496] 60 
minutes   
4.0 10/20/[ADDRESS_763339] Trial Protocol v 7.0 6 9/1/2023  4.0 10/20/22  16 Added footnote regarding 
pi[INVESTIGATOR_580497]   
4.0 10/20/22  5.2.1  Changed duloxetine dosage 
increase from gradual to 
increase after seven days, if no 
serious side effects   
4.0 10/20/22  5.2.1  Added participants who are 
currently breastfeeding will be 
excluded from duloxetine intervention  
4.0 10/20/22  7.1 Clarified the timing of the 
PROs and phenotypi[INVESTIGATOR_580498]   
4.0 10/20/22  9.2 Changed timing of batch 
sample shipments   
4.0 10/20/22  9.4 Changed duration of additional 
biomechanical assessment to 
50-60 minutes   
4.0 10/20/22  10.2.4 Removed log of minimum and 
maximum reading as a 
requirement   
4.0 10/20/22  14.1.3 Clarified that re -consent is 
allowed remotely with prior 
permission from DAC   
4.0 10/20/[ADDRESS_763340] number of 
pi[INVESTIGATOR_580499] a protocol 
deviation   
4.0 10/20/22  Appendix A  Updated Schedule of Activities   
4.0 11/4/22  8.4 Removed hardware between 
T12 and S1 as a 
contraindication for the MR S   
5.0 2/7/[ADDRESS_763341] -
Run-In PEG score as an 
eligibility criterion  
5.0 2/7/23  7.4 Removed in -person visit 
requirement for 
discontinuation   
5.0 2/7/23  7.4 Extended study length 
estimate   
5.0 2/7/[ADDRESS_763342] Trial Protocol v 7.0 7 9/1/2023  5.0 2/7/23  8.3 Added to and clarified 
duloxetine contraindications   
5.0 2/7/23  8.7 Added recruitment and 
retention referral language   
5.0 2/7/23  9.4, 9.5, 
9.6, 14.1.1  Clarified language regarding 
participation in additional 
(deep) phenotypi[INVESTIGATOR_007]   
5.0 2/7/23  10.2.1 Added Physical Therapi[INVESTIGATOR_11437]   
5.0 2/8/23  6.0 Corrected measurements 
informing stage 2 
randomization  
6.0 4/3/2023  9, 10.2.1, 
12.2, 12.3.1 Corrected references to a 
physical exam to instead 
reference the study physical 
assessment   
6.0 5/11/2023  8.7 Added online survey as 
recruitment method  ELC approval 5/10/2023  
6.0 5/15/2023  10.2.6 Added instructions for 
duloxetine dispensation at Visit 1 for sites who ship study 
medication   
6.0 5/15/2023  11.2 Added safety concerns for staff 
as a reason to discontinue a 
participant   
6.0 5/31/2023  12.3.4 Added that AEs followed until 
resolution, stabilization, or 
participant is off study.   
6.0 
6/15/2023  4.1, 7.1, 
7.4, SOA  Removed “subset of 
participants ” from Week 36 
assessment   
6.0 6/15/2023  7.4 Removed timeframe for end of 
study   
6.0 
6/16/2023  8.1 Removed respond to 5 emails 
during Run -in as an inclusion 
criterion  ELC decision 6/16/2023  
6.0 6/19/2023  4.1, 10.2.1  Added tapering instructions for 
duloxetine  ELC decision 5/31/2023  
6.0 6/19/2023  10.2.1 Added a reminder that study 
treatment will end in six weeks to 18 -week phone call, in case 
participant would like to schedule an appointment with their provider to continue their treatment after Visit 2.  ELC decision 6/7/[ADDRESS_763343] Trial Protocol v 7.0 8 9/1/2023  7.0 9/1/2023  4.1, 10.2.1  Added an additional week to 
the tapering period at the 
investigator or licensed 
designee’ s discretion  ELC decision 8/23/[ADDRESS_763344] Trial Protocol v 7.0 9 9/1/2023  2. STATEMENT OF COMPLIANCE  
This trial will be carried out in accordance with the [LOCATION_002] (US) Code of Federal Regulations (CFR) 
applicable to clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 
CFR Part 812) and NIAMS Terms and Conditions of Award. The study is being conducted under an NIH HEAL Initiative application.  
Princ ipal Investigators (PIs)  will assure that no deviation from or changes to the protocol will take place 
without prior agreement from the Back Pain Consortium (BACPAC) Research Program and NIAMS (as 
funding agency), and documented approval from the Institutional Review Board (IRB), except where 
necessary to eliminate an immediate hazard(s) to the trial participants. All personnel involved in the 
conduct of this study have completed Human Subjects Protection and ICH GCP Training.  
 The protocol, informed consent form(s), recruitment materials, and all participant materials will be submitted to the central IRB for review and approval.  Approval of both the protocol and the consent 
form must be obtained before any participant is enrolled.  Any amendment t o the protocol will require 
review and approval by [CONTACT_3484].  When changes are 
made to the consent form; a determination will be made regarding whether a new consent needs to be obtained from participants who had provided consent earlier using a previously approved consent form.  
  
 
BEST Trial Protocol v 7.0 10 9/1/[ADDRESS_763345]  
Ann Arbor, MI [ZIP_CODE] 
[PHONE_12040] 
[EMAIL_10362]  Protocol Co -Chair  
Gwendolyn Sowa, MD, PhD University of Pi[INVESTIGATOR_580500]  
[ADDRESS_763346] 
Pi[INVESTIGATOR_9109], PA [ZIP_CODE] 
[PHONE_12041] sowag [EMAIL_11043]  
  
Protocol Co -Chair  
Matt Mauck, MD PhD  
UNC Hospi[INVESTIGATOR_580501] [ADDRESS_763347], N2198 Chapel Hill NC [ZIP_CODE] -7010 
[PHONE_12042] [EMAIL_11044]  Protocol Co -Chair   
Kevin Anstrom, PhD  
University of North Carolina at Chapel Hill  
Department of Biostatistics  
[ADDRESS_763348]  
Chapel Hill, NC  [ZIP_CODE]  
[PHONE_12043] kevin.a [EMAIL_11045]  
  
BEST Trial Project Manager  
Rachel Goolsby  
[CONTACT_580575]  
[ADDRESS_763349]  
Chapel Hill, NC  [ZIP_CODE]  
[PHONE_12044] [EMAIL_11046]  
 BACPAC Project Director  
Anna Hoffmeyer, MPH  
University of North Carolina at Chapel Hill  
Collaborativ e Studies Coordinating Center  
[ADDRESS_763350]  
Chapel Hill, NC  [ZIP_CODE]  
[PHONE_12045] [EMAIL_11047]  
 
BEST Trial Lead Biostatistician  
Anastasia Ivanova, PhD 
University of North Carolina at Chapel Hill 
Department of Biostatistics  
3103-C McGavran -Greenberg Hall CB #7420  
Chapel Hill, NC [ZIP_CODE]  
([PHONE_12046] [EMAIL_11048]  
 
 
 
 
BEST Trial Protocol v 7.0 1 9/1/2023  4. PROTOCOL SUMMARY  
4.1. SYNOPSIS  
Title:  The BEST Trial: Biomarkers for Evaluating Spi[INVESTIGATOR_580502]:  Chronic low -back pain lasting three months or more with pain occurring 
on most days affects 10-20% of adults  in the [LOCATION_002] , and 
contributes to lost employment, disability , and, b y some estimates, $[ADDRESS_763351] effective in identifiable subgroups of participants.  
  
Study Des cription : The BEST  Trial (Biomarkers for Evaluating Spi[INVESTIGATOR_580503])  is a NIAMS -
sponsored  clinical trial being conducted through the NIH HEAL Initiative’s 
Back Pain Consortium (BACPAC) Research Program.  Generally, this trial 
will inform a precision medicine approach to the treatment of chronic 
 
BEST Trial Protocol v 7.0 2 9/1/2023  low-back pain ( cLBP ). BEST  is a multi -site, sequential, multiple assignment 
randomized trial (SMART) to evaluate four evidence- based interventions 
for chronic low-back pain. The trial is designed to meet the primary 
objective of estimating an algorithm for optimally assigning treatments based on an individual’s  phenotypic markers and response to treatment. 
Interventions being evaluated in this trial are: (1) enhanced self -care  
(ESC), (2) acceptance and commitment therapy (ACT), ( 3) duloxetine, and 
(4) evidence- based exercise and manua l therapy (EBEM) .  
 Each participant will complete an initial screening call and enrollment 
visit, followed by a [ADDRESS_763352] treatment period, eligible participants will be  randomly 
assigned to on e of the four study interventions. For the second treatment 
period, depending on response to their initial treatment, participants will 
be randomized to one of the following treatment actions: (1) maintain their current intervention, (2) augment their current intervention with 
another study intervention, or (3) switch to a new study intervention. For 
treatment actions (2) and (3), the additional or new intervention will be randomly determined independent of participant response to the initial 
treatment. Specific details on these treatment actions  are described in 
detail in Section 7. 
 All participants will undergo phenotypi[INVESTIGATOR_580504] 0, [ADDRESS_763353] ing of a more compreh ensive set of phenotypi[INVESTIGATOR_580505], at 
the same visits.  Section 9 provides a complete description of the 
phenotypi[INVESTIGATOR_580505].  
Pain, Enjoyment of Life, and General Activity (PEG) and Patient Global 
Impressions Scale (PGIC) will be assessed a t 6 weeks (midpoint o f 
intervention period one), 12 weeks (Visit 1), 18 weeks  (midpoint of 
intervention period two), 24 weeks (Visit 2), and [ADDRESS_763354] -baseline 
(12 weeks after intervention period two) . Basic safety assessments will 
also be performed at the se time points  to assess participant tolerability to 
their current study intervention(s). Patients who are unable to tolerate their assigned study treatment will be educated on how to safely discontinue their current treatment plan but will otherwise remain in the study.  
  
 
BEST Trial Protocol v 7.0 3 9/1/2023  Objectives:  
 The primary objective  is to estimate an algorithm to assign sequences of 
two cLBP treatments based on phenotypic markers and an individual 
patient’s response to the initial treatment ( i.e., a dynamic treatment 
regime  (DTR) ) that optimizes effectiveness. as characterized by [CONTACT_580576].  
The study has the following three secondary objectives : 
 
• Estimate  DTRs that  optimally balance multiple outcomes , taking 
into account participant preferences for outcomes  including pain 
intensity, pain interference, physical function, opi[INVESTIGATOR_2441], 
depression, anxiety, sleep duration and sleep disturbance.  
• Estimate DTRs that incorporate additional phenotypic markers 
(i.e., deep phenotypi[INVESTIGATOR_007]) collected on a subset of participants.  
• Assess whether effectiveness is sustained on outcomes collected 24 weeks after randomization to the second treatment.  
 
Analyses for secondary objectives will utilize the set of primary and secondary endpoints.  
 
The study has the following exp loratory objective s:  
• Evaluate the comparative effectiveness of individual treatments . 
• Evaluate the comparative effectiveness  of different treatment 
regimes (i.e., a particular regime with a given set of rules at each 
decision point ). 
• Evaluate the impact of treatment order on outcomes.   
   
 Analyses for exploratory objectives will utilize the set of primary and 
secondary endpoints.   
Endpoint s: The primary endpoint for the study is 24-week change  from baseline in 
patient-reported pain intensity and interference, measured with the Pain, Enjoyment of Life, and General Activity (PEG) scale .  
 Secondary endpoints are:  
• 24-week c hange from baseline in pain interference, measured 
with the 4 -item PROMIS Pain Interference scale (PROMIS-PI, 4a ) 
• Incidence of any opi[INVESTIGATOR_192842] [ADDRESS_763355] baseline.  
• 24-week c hange from baseline  in physical function, measured 
with the PROMIS -PF Short Form 6b . 
• 24-week c hange from baseline  in depression score,  measured 
with the PROMIS 4 -item depression scale from the PROMIS 29 
profile. 
• 24-week c hange from baseline  in anxiety score,  measured with 
the PROMIS Emotional Distress -Anxiety scale (PROMIS- EDA 4a) . 
• 24-week c hange from baseline  in sleep disturbance,  measured 
with the PROMIS short form 6a . 
• 24-week c hange from baseline  in sleep duration,  measured with 
the BACPAC sleep duration question.   
 
BEST Trial Protocol v 7.0 4 9/1/2023    
Study Population:  The study will enroll  adult participants who report having  low-back pain 
for at least [ADDRESS_763356] 1 8 years of age  and meet  other 
inclusion/exclusion criteria  as described in Section 8.  
  
Sample Size:  The study will enroll approximately 820 participants in order to obtain 
approximately 630 completers (i.e., 10% post -Run -in ineligibility and an 
additional 15% dropout rate  over the course of the trial  assumed ). 
Assuming dropout occurs uniformly across study interventions, the 
sample size of 630 will result in having approximately 80% probability of 
estimating a DTR within 90% of the optima l DTR  based on the study’s 
primary endpoint. Based on previous studies, it is estimated  that 
approximately 200 participants  will consent  to undergo comprehensive 
phenotypi[INVESTIGATOR_007] (i.e., phenotypi[INVESTIGATOR_580506]) . More details, including assumptions regarding 
intervention effect sizes can be found in Section 13.   
  
Interim Analysis:  Generally, this trial will  inform a precision medicine approach to the 
treatment of chronic low -back pain. In order to maintain sufficient power 
for the precision medicine analyses, interim analyses for futility or efficacy 
are not planned.  
  
Final Analysis:  Q-learning5,6 will be used to estimate a two -stage dynamic treatment 
regime that assigns a sequence of cLBP treatments based on phenotypic 
markers and the patient's response to treatment in order to maximize the 
expected reduction in PEG between the beginning and the end of the study. Q-learning reduces the reinforcement learning problem of optimizing a two -stage dynamic treatment regime to a standard 
regression problem, after which standard regression algorithms can be 
applied.  
  
Description of 
Sites /Facilities E nrolling 
Participants:  Approximately [ADDRESS_763357] ; all sites are 
clinic settings.  
  
  
Description of Study 
Intervention s: Acceptance Commitment Therapy  
ACT is a form of cognitive behavioral therap y that is well established for 
the treatment of chronic pa in7-12. The goal of ACT is to build psychological 
flexibility thereby [CONTACT_580577].  
Participants randomized to ACT will take part in [ADDRESS_763358] -supported 
online sessions (self -directed online modules supported by [CONTACT_580578]). Online sessions will focus on helpi[INVESTIGATOR_580507], 
connect with negative thoughts and emotions, develop mindfulness and identify and commit to values and goals that are important to them. 
During face -to-face sessions with the therapi[INVESTIGATOR_541], participants will be 
 
BEST Trial Protocol v 7.0 5 9/1/2023  encouraged to share their experience of skills pr actice and mastery, 
provide examples of skill use at home, and describe what barriers they 
encountered.  
 
Duloxetine  
Duloxetine is a serotonin norepi[INVESTIGATOR_26331] (SNRI) that is FDA-approved for use in cLBP
13, and, as such, is included as a 
recommended therapy in nearly all current treatment guidelines for low back pain.   Study participants will be treated with duloxetine for [ADDRESS_763359]  taper ing period will occur  in the 
13
thand 14th week s, as needed .  At the investigator or licensed designee’s 
discretion, tapering can be extended up to the 15th week.  
 
 
Enhanced Self -Care  
The Enhanced Self -Care intervention will be comprised of educational 
modules on  evidence -based cognitive- behavioral self -management skills 
for pain14. These modules will be provided digitally for self -administration 
over a period of [ADDRESS_763360] associated with the 
delivery of these educational materials ; however, automated text or email 
messages will guide participants to specific content.  Everyone receives the same ESC materials for weeks 1 -4, after which the text/email guidance 
offers personalized recommendations for accessing additional modules 
based upon identified problems from the baseline assessment.  
Additionally, the embedded walking program module will utilize Fitbit 
step tracking to allow participants to monitor their walking progress.  
Evidence -Based Exercise and Manual Therapy  
Licensed physical therapi[INVESTIGATOR_11437]  (PTs)  or Doctors of Chiropractic (DCs)  will rely 
on evidence -based guidance to direct decision -making on the particular 
type of manual  and exercise therapy that may be best suited to an 
individual study participant
15. Special attention will be paid to the 
clinician’s choice of language in regard to the purpose and expected 
outcomes of manual therapy in order to avoid enhancing catastrophizing ideations or preference for passive interventions.  A total of [ADDRESS_763361] approximately 60 minutes each.  
 
Study Duration:  The BEST trial  will run a pproximately [ADDRESS_763362] Trial Protocol v 7.0 6 9/1/2023  Participant Duration:  The study duration for most participant s will be 3 8 weeks . This includes 
the 2-week screening/run -in period, two [ADDRESS_763363] Trial Protocol v 7.0 7 9/1/2023  4.3. SCHEDULE OF ACTIVITIES (SOA)  
See Appendix  A 
5. INTRODUCTION  
5.1. STUDY BACKGROUND  AND RATIONALE  
Chronic l ow-back pain is a highly prevalent pain condition among adults  that diminishes both physical 
and psychosocial wellbeing4. Chronic low -back pain lasting three months or more with pain occurring on 
most days affects 10 -20% of adults1, and 28% report back pain in the past three months4. Chronic low -
back pain contributes  to lost employment, disability, and, by [CONTACT_137006], $[ADDRESS_763364]-line recommendations for chronic low -back pain are often 
non-steroidal anti -inflammatory drugs (NSAIDS ) and exercise for patients who experience non-
immobilizing pain , and opi[INVESTIGATOR_580508]20,21.  
Research into optimum treatment for chronic low -back pain is challenged by [CONTACT_580579], the varied phenotypes of back pain patients , and  difficulty assessing both the cause of pain and 
treatment effect.  Trial design and retention issues limit our understanding of treatments  and their 
effect . While individual trials of single or multi -modal interventions have demonstrated moderate 
treatment effects, heterogeneity of trial design, outcomes, and populations stymie large -scale 
systematic reviews22 as well as reviews of specific treatment approaches19. These methodological factors 
highlight the need for large -scale trials with standardized measures, treatments, and outcome 
measures. Addi tional research priorities include patient phenotypi[INVESTIGATOR_521306] -group stratification and 
the development of pharmacological and non -pharmacological first -line treatments for chronic low -back 
pain23. The proposed BEST trial  will harmonize recruitment, enrollment, data collection, and retention 
strategies across multiple sites, each of which will recruit from a diverse population of chronic low -back 
pain patients. Drawing on expertise from within and outside of the consortium, sites will ado pt 
ambitious recruitment and retention goals. Given historic underrepresentation of minority communities 
in research, the consortium will closely monitor  recruitment of underrepresented communities and 
initiate oversampling, as needed . 
The NIH  supports the discovery and testing of novel non -addictive pain treatments  to stem the ongoing 
opi[INVESTIGATOR_580509]2. BACP AC, a funded 
component of the NIH’s Helpi[INVESTIGATOR_272919]- term (HEAL) initiative, is a multisite consortium 
which will advance treatment of chronic low -back pain by  [CONTACT_2931] a precision medicine approach  to 
identify specific  treatments or combinations of treatments that are most effective in identifiable 
subgroups of participants.  
 
BEST Trial Protocol v 7.0 8 9/1/[ADDRESS_763365] been clinically 
proven to be effective for some populations. The interventions to be included in the trial are: enhanced 
self-care (ESC), which incorporates self -management techniques and education, a cceptance and 
commitment therapy (ACT), duloxetine, and evidence-based exercise and manual therapy (EBEM)10,13- 15. 
The trial  will build on this knowledge base by [CONTACT_2931] a precision medicine approach to these proven 
interventions to determine the optimal treatment for specific participant subgroups.  This precision 
medicine approach is designed to estimate an algorithm to assign sequences of two cLBP treatments based on an individual participant’s changing response and phenotypic markers and may help to reduce reliance on opi[INVESTIGATOR_580510].  
5.2. RISK/BENEFIT ASSESSM ENT   
  
5.2.1.  KNOWN POTENTIAL  RISKS  
 
Participants taking part in this study will be exposed to risks that are viewed as similar to those 
encountered in a standard clinical practice and would be deemed as having no more than a moderate 
risk level. The following section describes specific risks associated with undergoing phenotypi[INVESTIGATOR_107340], receiving study interventions, and disclosure of confidential information  (i.e., breaches of 
confidentiality).  
Risks Associated with Phenotypic Assessments  
Questionnaires:  Questionnaires pertaining to pain, medication  use, and history  of chronic low -back pain 
and other pertinent comorbidities  will be d elivered as part of the study and may be considered 
burdensome and repetitive. Some participant s may feel minor discomfort sharing information about 
topi[INVESTIGATOR_580511], mental health , and  substance use.   
Blood Draw / Venipuncture : Collection of blood is occasionally associated with minor bruising, risk of 
infection, discomfort, feeling light- headed, or fainting . 
Stool collection: Participants will be asked to provide a stool sample which will be used to analyze gut microbiome. Stool samples may contain germs that may cause or spread infection if proper hygiene methods are not followed.  
Biomechanic al Assessment: All participants  will receive at least one biomechanical assessment, part of 
which requires the use of wear able technology to assess biomechanical  factors related to chronic low -
back pain. Participants might find wearable technology uncomfortable and may experience light low 
back muscle fatigue or soreness similar to a light workout the day following the motion assessment .  
Less common are s hort-term aggravation of existing low back symptoms; irritation, pi[INVESTIGATOR_38633], rubbing, or 
sticking of skin from motion harness components; pi[INVESTIGATOR_580512] ( e.g.,  insulin 
pump) snagging during the motion testing, and loss of balance while performing the motion assessment causing a fall.  
Adhesive may be used to affix wear able sensors during assessments. These adhesives may cause short -
term, minor skin irritation in some patients.  A subset of participants will use wearable technology continuously for seven days, which participants may find burdensome. These assessments may  also 
cause minor physical discomfort or tiredness but are unlikely to cause long- term physical discomfort.  
 
BEST Trial Protocol v 7.0 9 9/1/2023  Imaging: All participants  will undergo Magnetic Resonance Imaging (MRI) of the spi[INVESTIGATOR_050]. A subset of 
participants  may  undergo MRI of the brain  and an additional  spi[INVESTIGATOR_580513] .  MRI is safe for most participant s but is contraindicated for certain subsets  of people, such 
as those with certain medical devices ( e.g.,  implanted cardiac devices, cochlear implants, or intr acranial 
aneurism clips) or with ferrous metal in their body ( e.g.,  wire mesh, screws). MRI is not safe for pregnant 
women. While MRI is safe for most participant s, the procedure may cause some participants to feel 
emotional discomfort, anxiety, and claustrophobia. The noise of MRI requires participant s to wear ear 
protection and may cause peripheral muscle or nerve stimulation.  
Quantitative Sensory Testing (QST) : QST may cause minor but temporary physical discomfort.  
Specifically, the manual pressure algometer and pin prick stimulus are commonly used in QST studies 
and will not cause tissue injury at the maximum forces applied in this study. However, these instru ments 
may cause minor physical discomfort in the areas of testing; this discomfort  is expected to resolve 
within minutes of test completion.  C onditioned Pain Modulation  (CPM) assessments using cold stimuli 
are also uncomfortable but will be limited in int ensity and duration to prevent tissue damage.  The cold -
water bath component of the QST assessment is contraindicated for  certain  participants with 
uncontrolled high blood pressure, heart conditions, and a history of Raynaud’s Syndrome.  
Genetic Analysis  & Information: The risks related to genetic analyses can be to individuals or groups. 
These harms include stigmatization and impact insurability for life, disability, and long -term care 
insurance. If stored genetic information were re-connected to a participant’s identity , personal 
information about the participant  and the participant’s  health and risk of disease could become known 
to others. This could present unknown risks.  
Risks Associated with Study Interventions  and Run- in Activities  
Acceptance Commitment Therapy  (ACT) : The ACT behavioral intervention includes discussing one’s  pain 
experience with a trained therapi[INVESTIGATOR_580514]. These 
risks are minimal and are sometimes part of the therapeutic process. To reduce the disabling effects of depression, fear or other feelings, one may need to first recognize these before identifying healthy goals 
for improvement. Participants  will meet with an  assigned therapi[INVESTIGATOR_580515]. The  therapi[INVESTIGATOR_580516]. They will 
provide ongoing support over the course of treatment and, if applicable, will monitor the pa rticipant for 
worsening of depression or anxiety symptoms. Study participants may also reach out to study staff with any questions or concerns throughout the course of the study.  
Duloxetine: Duloxetine will be administered with daily doses ranging from 30m g to [ADDRESS_763366] common side effects with this drug, which  
include nausea, vomiting, nausea, dry mouth, constipation, diarrhea, fatigue, and difficulty sleepi[INVESTIGATOR_007]. All of these side effects are thought to be less common with slow gradual dose escalation, and many (especially gastrointestinal intolerance) typi[INVESTIGATOR_580517]. The most serious adverse effect associated with duloxetine is the increased risk of suicidality with initiation, especially in individuals 
under age 25. Participants on duloxetine (of all ages) will be monitored appropriately for clinical 
worsening, suicidality, or unusual changes in behavior.  Participants reporting a history of bipolar 
disorder, manic epi[INVESTIGATOR_1841], or suicide attempts  and participants who are currently breastfeeding will not 
be eligible for participation in the Duloxetine intervention.  
 
BEST Trial Protocol v 7.0 10 9/1/2023  Enhanced Self Care  (ESC) :  The ESC intervention is an educational and self -care digital intervention.  
Risks are minimal.  
Evidence-Based Exercise and Manual Therapy  (EBEM):  Manual therapy may be used to reduce pain and 
stiffness and improve range of motion, and exercises may be used to improve muscle strength, flexibility 
and endurance.  Both are considered safe for the treatment of low -back pain, but side effects associated 
with spi[INVESTIGATOR_580518]/manipulation and therapeutic exercise are common and benign. Approximately 50% of patients report local post -manipulation or exercise muscle and/or joint soreness which typi[INVESTIGATOR_197726] [ADDRESS_763367] of their low back pain on various aspects of his or her life possibly resulting in emotional 
distress. EBEM is contraindicated for certain participants with uncontrolled high blood pressure or heart 
conditions . 
Run-in:  The Run -in period is comprised of inf ormational materials delivered digitally. Risks are minimal.  
Risks Associated with Confidential Information  Disclosure 
Despi[INVESTIGATOR_580519] (e.g., protected health information  (PHI)), breaches of confidentiality, while very unlikely, are possible. An 
example breach of confidentiality is the disclosure of a participant’s protected health information to a 
party that is not approved to have access to that information. A breach of confid entiality will be 
considered as an unanticipated problem and, as such, will be reported to the IRB of record within [ADDRESS_763368] been independently shown to clinically improve pain  
intensity10,14,18,24- 28 and may improve other outcomes such as function or pain interference; however, 
neither improvement nor direct benefit is guaranteed to study participants. Study participants who 
improve on the treatment to which they are randomized will be allowed to continue that treatment 
either as a single treatment or augmented with an additional treatment. Participants who do not improve on the treatment to which they are rand omized will be randomized to a new treatment.  All 
study treatments will be provided free of charge to participants. Participants may also benefit by [CONTACT_580580]-management techniques. Participants may experience psychological benefit from interacting with study staff and personnel. 
Participation in the study  may be beneficial to participant s’ general health, as participants might initiate 
and maintain healthy habits such as exercise. These be nefits, if incurred, may be both immediate and 
long-term.  
This research has the potential to benefit society in general by [CONTACT_580581] -back 
pain. Chronic low -back pain is a major cause of disability in the [LOCATION_002] and causes both physical 
and emotional suffering. Patients are often unable to find adequate treatment for their condition , given 
the heterogeneity of patient phenotype including biomarkers, pain etiology and mechanism, and psychosocial characteristics. The goal of t he study  is to apply a precision medicine approach to chronic 
low-back pain treatment, which will allow more patients to receive the treatment that is likely to be best 
 
BEST Trial Protocol v 7.0 11 9/1/[ADDRESS_763369] for the study. The informed consent process will be administered by [CONTACT_580582]. This explanation will include describing the purpose of the study, phenotypi[INVESTIGATOR_580520], the time commitment required, all inclusion/exclusion criteria, potential risks  and benefits, monetary and 
non-monetary compensation, study personnel contact [CONTACT_3031], and information on how study data and biospecimens will be shared within the BACPAC Consortium and with NIH approved repositories. All participants will be allowed to ask questions on any aspect of the protocol , and study personnel will 
provide answers and confirm there is no residual uncertainty regarding the study procedures prior to obtaining informed consent from the participant.  
General Risk Mitigation  Procedures  
Protection of subjects from risk is multifaceted  and includes monitoring the safety of the research 
participants, putting in place processes for minimizing research-associated risk, maintaining 
confidentiality of study data and participant iden tification, and review ing and reporting adverse and 
unanticipated events.  
Study staff a t each site will be trained in HIPAA, CITI, and other human subjects research standards  as 
required by [CONTACT_3725]’s institutional requirements. The Data Integration, Algorithm Development and 
Operations Management Center (DAC) will hold central training on study procedures and systems for clinical personnel prior to the start of the study and record these sessions for use by [CONTACT_580583].  If new procedures or forms are adopted during the study, additional 
training will be conducted via webinars.  New clinical center staff will be trained by [CONTACT_580584].  Each clinical site staff member will be certified on study procedures and systems, and certification records will be maintained at the sites for auditing. Each intervention arm will be delivered by [CONTACT_580585].  
The measures taken to minimi ze risk associated with phenotypic assessments and study interventions 
are described below.   
Risk Assessment & Mitigation for Phenotypic Assessments  
Participants will be screened for contraindications to any of the BEST phenotypi[INVESTIGATOR_580521]. All phenotypi[INVESTIGATOR_160981] (e.g., quantitative sensory testing, biomechanical 
assessments, blood draws) will be performed by [CONTACT_580586] , where applicable,  licensed 
personnel ). Particip ating sites will be staffed by [CONTACT_580587] -back pain, and the DAC will be responsible for ensuring all staff are trained and 
certified as required by [CONTACT_580588].  
Questionnaires:  To minimize patient burden associated with completing a large number of 
questionnaires,  as much as is feasible without sacrificing the validity of the data, participants will be 
 
BEST Trial Protocol v 7.0 12 9/1/[ADDRESS_763370] the option to terminate participation without penalty and/or will be  assisted in arranging 
medical/ psychiatric help, if necessary. 
Blood Draw / Venipuncture:  In order to minimize risk of infection, venipuncture will be performed by 
[CONTACT_580589].  Alcohol will be swabbed over the region of venipuncture prior to the procedure and a sterile bandage will be applied following the procedure.  
Stool collection: Instructions regarding the safe collection of stool will be provided with each stool 
collection kit.  
Biomechanical Assessment: Biomechanic al assessments will be supervised by [CONTACT_32341].  Participants 
will be instructed that they can contact [CONTACT_580590] a n assessment.   
Imaging:  The primary established hazard associated with MR imaging is that the magnet exerts  a strong 
force on metal objects. For this reason, metal objects are excluded from the vicinity of the magnet so that they will not become projectiles. In addition, each subject undergoes a standard screening procedure to determine whether they have any implanted materials that may pose a risk.  If there is any doubt about the nature of any implanted material, the subject will not be scanned. Participants will be instructed to bring or wear clothing without metal fasteners and remove jewelry and any other m etal 
objects from their body. Participants will wear foam earplugs or headphones to reduce the loud noises 
made by [CONTACT_218862]. Participants will be able to communicate with the examiner throughout the scan. If needed, the participant will be removed immediately from the scanner. MRI s essions will be 
conducted by [CONTACT_21724].  Participants will  be encouraged to contact [CONTACT_580591]. The investigators have extensive prior 
experience in the utilization of MRI for research. The MRI machine is operated within FDA guidelines so 
the potential for inducing peripheral nerve stimulation  is low. Participants who report pregnancy will be 
excluded from MRI portion of the protocol. 
Quantitative Sensory Testing (QST):  Study personnel  will be trained by [CONTACT_580592]. Participants will be instructed that they can stop any QST 
procedure anytime that the pain or unpleasantness of the task becomes unbearable. All procedures have b een thoroughly evaluated for reliability and safety, and are well tolerated by [CONTACT_580593], causing no more than temporary mild discomfort in the body regions that will be evaluated. 
Genetic Analysis:  Current federal law will help protect  study participants  from genetic discrimination in 
health insurance and employment.  
Risk Assessment & Mitigation for Study Interventions  
Participants will be screened for contraindications to any of the BEST study interventions prior to 
enrolling in the study. Participants who have a contraindication to a study intervention and who are 
 
BEST Trial Protocol v 7.0 13 9/1/[ADDRESS_763371] a contraindication. In Section s 10.1  (Acceptance Commitment 
Therapy), 10.2  (Duloxetine), 10.3  (Enhanced Self Care), and 10.4  (Evidence-Based Exercise and Manual 
Therapy ) specific details regarding risk assessment and mitigation are given for each study intervention.  
Participants will be advised that they should contact [CONTACT_580594]. Prior to the start of a new study intervention, 
participants wi ll be informed that if they are unable to tolerate the intervention, they are permitted to 
cease the intervention.  Specifically for duloxetine, participants will be instructed on how to safely taper off the medication. In addition, study staff will conduct a phone call assessment with all participants approximately midway into each of the two intervention periods to evaluate pain -related outcomes as 
well as to ascertain how well the participant is tolerating their current study intervention(s). Participants who indicate they are unable to tolerate the intervention will be safely transitioned off their current intervention but, if in intervention period one, will be allowed to be randomized to a new intervention in the second study period. Additionally, all participants will be assessed for unexpected and adverse events 4 weeks after the end of the second intervention period  (i.e., after completion of all study 
treatment).    
Acceptance Commitment Therapy :   Participants will interact with their therapi[INVESTIGATOR_580522], and 
the therapi[INVESTIGATOR_580523]. Participants will be encouraged to contact [CONTACT_464] w ith questions or 
concerns throughout the course of the study.  
 Duloxetine : Participants on duloxetine will be monitored appropriately for clinical worsening, suicidality, 
or unusual changes in behavior. Participants may be referred for appropriate treatme nt including 
emergency services if required. Participation can also be discontinued if there is active suicidal ideation.  
 Enhanced Self Care:   The ESC intervention is an educational and self -care digital intervention.  Risks are 
minimal;  therefore, no intervention-specific risk mitigation is planned.  
 
Evidence-Based Exercise and Manual Therapy :   The EBEM intervention will be delivered by [CONTACT_580595][INVESTIGATOR_580524] .  Participants who report local post -manipulation or 
exer cise muscle and/or joint soreness will be instructed on appropriate self -care. 
 
Run-in :  The Run -in period is comprised of informational materials delivered digitally. Risks are minimal; 
therefore, no intervention- specific risk mitigation is planned.  
 
Risk Assessment & Mitigation for Disclosure of Confidential Information  
Several measures have been taken to minimize the risk of breach of confidentiality via unintended 
disclosure of confidential information. These include the general risk mitigation procedur es described 
above (e.g., ensuring study staff have completed HIPAA, CITI, and other human subjects research 
training), providing highly secure electronic data collection systems and procedures (as described in 
Section 14), and collecting only essential identifiable information that is required for the stud y’s 
scientific objectives and for critical operational reasons (e.g., contact [CONTACT_580596]).  
All reasonable steps will be taken to protect the privacy of participants.  Each study participant will be 
assigned a unique study ID upon enrollment . All data and other artifacts collected for the study will be 
 
BEST Trial Protocol v 7.0 14 9/1/2023  identified by [CONTACT_2299]’s study ID. This includes data collected using the Carolina Data Acquisition 
and Reporting Tool (CDART) data management system, the online survey platform s, biospecimens, and 
web-based applications . Personally identifiable information will be s egregated from other data. CDART 
implements a granular authorization model and enforces the principle of lease privilege access. Only a 
restricted set of authorized users will be allowed access to enter or view personal information. To further restrict data access, the CDART database is behind a network firewall which is open only to the 
CDART system itself.   
The CDART data management system has robust security features including unique user logins with expi[INVESTIGATOR_580525]; storage of hashed passwords only; granular permissions based on user requ irement to enforce the principle of least privilege access; and encrypted 
data transmission. The secure server environment where the systems that host CDART reside is located within a hardened data center on the UNC campus and is governed by [CONTACT_580597] i nformation 
security guidelines. Weekly vulnerability detection scans are performed using third -party  vendor  
scanning tools, which include full administrative credentials to perform maximum detection techniques. Real -time virus protection software is implemented, and weekly full system virus scans are performed. 
Daily backups of the data are made and stored in an off -site location. CDART is 21 FDA Part 11 
compliant.  
5.2.4.  RISK/BENEFIT JUSTIFI CATION  
The risks associated with phenotypi[INVESTIGATOR_580526]. A greater understanding of the 
biomarkers, biomechanics, and etiology of chronic pain will improve future treatment  recommendations  
and enhance quality of life for chronic low -back pain patients.  
The risks associated with study procedures and interventions are generally minimal. The components of 
each of the  study interventions have been previously studied and are in current clinical practice. There 
are well-studied side effects associated with duloxetine, but these side effects are generally mild to 
moderate for participants. Moreover, participants will be monitored for side effects and advised to discontinue if duloxetine is not well tolerated. These non -invasive treatments may reduce pain intensity, 
improve function, enhance self -management capacity, and i ncrease psychological flexibility. Altogether, 
the potential benefit of these interventions outweighs the potential risk . The screening and monitoring 
of participants by [CONTACT_580598].  
6. OBJECTIVES AND ENDPOINTS 
 The BEST Tria l will inform a precision medicine approach to cLBP  and is designed to identify treatments 
that are most effective in identifiable subgroups of patients. Therefore, the study  was designed to 
estimate dynamic treatment regimes rather than to test the overal l effectiveness of any single 
intervention or combination of interventions.  
 
The primary objective  is to estimate an algorithm to assign sequences of two cLBP treatments based 
on phenotypic markers and an individual patient’s response to the initial treatment (i.e.,  a dynamic 
treatment regime) that optimizes effectiveness.  
 In this trial, phenotypic markers will not be used to assign treatments, rather particip ants will be 
randomly assigned to treatment.  Response to initial treatment will guide second-stage randomization  
and will be assessed with the Pain, Enjoyment of Life, and General Activity (PEG) scale a nd the Patient 
 
BEST Trial Protocol v 7.0 15 9/1/2023  Global Impression of Change (PGIC) [ADDRESS_763372] randomization. The primary analysis will 
then estimate an algorithm that can be applied to cLBP patients  that will optimally assign treatments 
based on a patient’s phenotypic markers and changing response (a dynamic treatment regime or  DTR).  
Phenotypic markers that will be considered include, for example, preference for treatment and outcome 
priorities, history of depression, and time since diagnosis of chronic back pain. Study participant 
phenotypic markers will be assessed at baseline and a subset will be measured at the end of the first 
intervention period. As part of this analysis, we will compare the estimated best DTR that does not  use 
phenotypic variables or participant response with the estimated optimal DTR  A hypothetical example of 
a DTR that we might estimate would involve a sequence of two decision rules: Individuals with chronic 
low-back pain receive physical therapy for 12 weeks and if pain intensity and interference are below a  
given threshold, continue regular follow up with patient; if pain interference is over the threshold, provide patient with prescription for duloxetine for 12 weeks.  
 
This procedure will be applied to the following primary and secondary endpoints : 
 
• Primary endpoint: 24-week c hange from baseline in patient -reported pain intensity and 
interference , measured with the Pain, Enjoyment of Life, and General Activity (PEG) scale at 
Visits 0 (baseline) and 2 ( 24 weeks of treatment )  
• 24-week change from baseline in pain interference , measured with the 4 -item PROMIS Pain 
Interference scale (PROMIS -PI, 4a) at Visits 0 (baseline) and 2 (24 weeks of treatment)  
• Incidence of opi[INVESTIGATOR_2441],  measured by [CONTACT_6270] -report at Visit 2 ( 24 weeks of treatment )  
• 24-week change from baseline in physical function , measured with the PROMIS -PF Short 
Form 6b at Visits 0 (baseline) and 2 (24 weeks of treatment)  
• 24-week change from baseline in depression score , measured with the PROMIS 4-item 
depression scale from the PROMIS 29 profile at Visits 0 (baseline) and 2 (24 weeks of treatment)  
• 24-week change from baseline in anxiety score , measured with the PROMIS Emotional 
Distress-Anxiety scale (PROMIS -EDA 4a) at Visits 0 (baseline) and 2 (24 weeks of treatment)  
• 24-week change from baseline  in sleep disturbance,  measured with the PROMIS short form 
6a at Visits 0 (baseline) and 2 (24 weeks of treatment)  
• 24-week change from baseline  in sleep duration, measured at Visits 0 (baseline) and 2 (24 
weeks of treatment)  
 
The PEG is  a 3-item assessment of pain intensity and interference with enjoyment of life and general 
activity over the past week. This scale is validated, has low participant burden, is responsive to change , 
and captures multiple core outcome domains recommended by [CONTACT_7902], 
Measurement, and Pain Assessment in Clinical Trials (IMMPACT)  and that are valued by [CONTACT_580599] .
29-[ADDRESS_763373] Trial Protocol v 7.0 16 9/1/[ADDRESS_763374] . 
 
The study has the following 3 secondary objectives : 
 
Estimate DTRs that optimally balance multiple outcomes, taking into account participant preferences for outcomes  including pain intensity, pain interference, physical function, opi[INVESTIGATOR_2441], depression, 
anxiety, sleep duration and sleep disturbance.  
Identification of DTRs that appropriately balance multiple outcomes will be accomplished by [CONTACT_580600] (Visit 0 and Visit 1 ) as well as 
overall satisfaction of the treatment at 12 and 24 weeks. This participant preference information will not 
be used to assign treatment during the study but will be used to estimate a participant -preference 
based DTR. The participant preference tool , CAPER, has been designed for use in this study and will be   
validated as part of its ongoing development in a BACPAC ancillary study.  
Estimate  DTRs that incorporate additional phenotypic markers (i.e., deep phenotypi[INVESTIGATOR_007]) collected on a 
sub-set of particip ants.  
 A subset of participants ( ~n=200 ) will undergo ‘deep’ phenotypi[INVESTIGATOR_580527], functional brain imaging,  and qualitative sensory testing. We will apply 
procedures discussed for the primary objective  to estimate and identify DTRs to evaluate in future 
studies. While the precision of these estimates will be lower given the reduced sample size, we will learn what additional phenotypic measures may predict differential response to treatment.  
 
Assess whet her effectiveness is sustained  on outcomes collected 24 weeks after randomization to the 
second treatment.  
 
Endpoints will be the same as listed for the primary objective except that they will be measured at the final study visit (Visit 3 ) occurring 24 wee ks after the second -stage randomization. Assessment of this 
aim will utilize procedures discussed for the primary objective.  
 
The study has the following 3 exploratory objectives : 
 Evaluate the comparative effectiveness of individual treatments.  
Evaluate the comparative effectiveness of different treatment regimes (i.e., a particular regime with a 
given set of rules at each decision point).  
Evaluate the impact of treatment order on outcomes.  
 For t hese analys es we will estimate average treatment effects. Endpoints will include the primary and 
secondary endpoints identified in the primary objective, measured at [ADDRESS_763375] Trial Protocol v 7.0 17 9/1/2023   
This study is a multi -site, sequential, multiple assignment randomized trial (SMART) to estimate DTRs 
based on  four evidence -based interventions for chronic low -back pain. The trial is designed to meet the 
primary objective of estimating an algorithm for optimally assigning treatments based on an individual 
patient’s phenotypic markers and  response to treatment. Interventions being evaluated in this trial are: 
(1) enhanced self -care  (ESC), (2) acceptance and commitment therapy (ACT), (3) duloxetine, and (4)  
evidence-based exercise and manual therapy (EBEM) .  
 Each participant will complete a n initial screening call and enrollment visit, followed by a [ADDRESS_763376] treatment 
period, participants will be randomly assi gned at Visit 0 to one of the four study interventions. For the 
second treatment period, depending on response to their initial treatment, participants will be assigned to: (1) maintain their current intervention, (2) augment their current intervention with another study intervention, or (3) switch to a new study intervention. For treatment actions (2) and (3), the additional or new intervention will be randomly determined independent of participant response to the initial treatment.  Patient R eported Outcome (PRO) assessments will be performed at baseline (Visit 0/Week 0) 
and at Weeks 6, 12, 18, 24, and 36, and phenotypi[INVESTIGATOR_580528] (Visit 0/Week 0) and at Weeks 12 and 24 (Visits 1 and 2)  
 At the end of the run -in period, participants will be re -assessed for eligibility. Those meeting 
requirements for randomization (Section 8) will be randomized to one of the [ADDRESS_763377] line treatments.  At 
the baseline visit (Visit 0), all participants will undergo baseline data collection and phenotypi[INVESTIGATOR_007]. Data 
collected for phenotypi[INVESTIGATOR_580529]-reported outcomes, spi[INVESTIGATOR_321728], biomechanical 
assessments, and collection of blood and stool. As described in Section 5.2.2 , some of these data will be 
collected at home prior to the in-person portion  of the study visit. A subset of eligible and willing 
participants (~n=200) will undergo additional phenotypi[INVESTIGATOR_007]. Details of the p henotypi[INVESTIGATOR_580530] 9 . A subset of phenotypic markers w ill be re-assessed Week 12 (Visit 1) and Week 24 
(Visit 2). 
 Participants will be assessed for response to treatment Week 12  (Visit 1) and Week 24 (Visit 2)  using the 
PGIC and PEG. Participants  will be grouped into one of four responder classes using the PGIC and PEG 
(see Section 7.1) and assigned to the following based on their responses:  
• maintain current treatment (PGIC=1 -2, PEG <4),  
• augment the current treatment with a randomly selected additional treatment (PGIC=1 -2, 
PEG ≥4),  
• be randomized to augmentation or switching to a new treatment (PGIC=3 -4), or  
• switch to a randomly selected new treatment (PGIC=5 -7)  
  
Since the ESC modules focus on self-care, education and a walking program, requiring participants in this intervention arm to cease these activities is not practical; therefore, individuals assigned to ESC at the 
first randomization will maintain ESC if PG IC is 1-2 and PEG<[ADDRESS_763378] Trial Protocol v 7.0 18 9/1/[ADDRESS_763379]-line treatment until the end of the 12 -week treatment period.  
 
All participants will also receive an assessment 4 weeks after the end of the second treatment period for 
safety purposes  (week 28) . Participants , who se randomization to the first intervention is at least 36 
weeks prior to the end of data collection,  will be assessed for outcomes at 36 weeks.  
 
Participants may need to discontinue treatments prior to  the end of the 12 -week treatment period  (e.g., 
following an adverse reaction to duloxetine; see Section 10.2.[ADDRESS_763380] of reasons) . Participants  needing  
to discontinue first period treatment will be switched to a randomly selected second treatment at Visit 
1.  Participants needing to discontinue second period treatment will remain in the study and undergo all  
future  assessments for which they are eligible. 
 
The study will enroll approximately [ADDRESS_763381] approximately 630 completers  (i.e., 15% dropout rate after randomization  
assumed).  Assuming dropout occurs uniformly across study interventions, the sample size of 740 
randomized will result in having approximately 80% probability of estimating a DTR within 90% of the 
optimal DTR based on the study’s primary endpoint. See Section 13.[ADDRESS_763382]. Generally, this trial will  inform a 
precision medicine approach to the treatment of chronic lo w-back pain and therefore we are not 
planning interim analyses for futility or efficacy in order to maintain sufficient power for the precision medicine analyses. Blinding is not feasible for study participants or staff involved in the delivery of 
interven tions. Investigators involved in the analysis of study data will be blinded to treatment 
assignment.  
 The study timeline involves approximately 9 months of participant enrollment across 1 2 sites for a total 
of 820 enrolled . Sites will enroll ~ 7 participants per month. We anticipate that ~90% of participants who 
consent at the Enrollment Visit will be randomized at the end of the 2 -week run -in at Visit 0 and that 
85% of randomized participants will complete all study activities. The total study duration for all participant s is [ADDRESS_763383] a sequential, multiple assignment, 
randomized trial (SMART).  
 
BEST Trial Protocol v 7.0 19 9/1/2023  7.3. JUSTIFICATION FOR DO SE/INTERVENTION REGIMENS  
The justifications for doses for individual treatments are found in Sections 10.  
7.4. END OF STUDY DEFINITION  
For study non-completers, the end of the study will coincide with the point in time when the participant 
notifies study personnel that they wish to dis continue the study. If the reason for study discontinuation 
is related to an incidence adverse event, and if the participant consents to further contact [CONTACT_580601], 
the participant will be contact[CONTACT_3012] 4 weeks after completion of the study discon tinuation visit to 
follow up on adverse events and document their resolution or status . 
The study will end approximately 38 weeks after randomization ( at the time of  completion of the [ADDRESS_763384]-int ervention follow-up period ).  
8. STUDY POPULATION  
8.1. STUDY INCLUSION CRITERIA  
To be eligible, an individual must meet all of the following inclusion criteria:  
• Ability to read and understand English  
• Provision of signed and dated informed consent form(s)  
• Willing and able to receive study -related messages and survey  links via email  
• Willing and able to receive study -related phone calls  
• Age 18 years old or older  
• Low-back pain for at least [ADDRESS_763385] 6 months  
• Contraindicated to no more than one of the study interventions  at the time of eligibility 
assessment(s)  
• Eligible to receive at least three of the four study interventions and willing to receive any 
intervention for which they are eligible  
• A PEG score 4 or higher prior to the Run -in period  
• Willing and able to undergo required phenotypi[INVESTIGATOR_48891] 9  
• Regular reliable access to an internet -enabled device such as a smart phone, tablet, or laptop 
computer  
• Meet Run -in period engagement eligibility criteria:  
o Completion of two Run -in study information modules prior to period 1 randomization 
(Visit 0 ) 
• Low-back pain more severe than pain in other parts of the body  
• Available to complete the full study protocol (approximately 9 months)  
8.2. STUDY EXCLUSION CRITERIA  
 
An individual who meets any of the following criteria will be excluded from participation in this study:  
• Pregnant at the time of Visit 0 (Baseline)  
• Affirmative participant response to any of the following conditions: 
o Progressive neurodegenerative disease  
o History of discitis osteomyelitis (spi[INVESTIGATOR_31506]) or spi[INVESTIGATOR_580531] v 7.0 20 9/1/2023  o History of ankylosing spondylitis, rheumatoid arthritis, polymyalgia rheumatica, psoriatic 
arthritis, or lupus  
o History of cauda equina syndrome or spi[INVESTIGATOR_580532] 
(strength <4/5 on manual motor testing)  
o Diagnosis of any vertebral fracture in the last [ADDRESS_763386] 24 months  
o Visual or hearing difficulties that would preclude participation  
o Uncontrolled drug/alcohol addiction  
o Individuals actively pursuing disability or workers compensation or involved in active 
personal injury -related litigation  
o Currently participating in another interventional pain study  
• Any condition that, in the opi[INVESTIGATOR_871], would preclude the patient from being able 
to safely participate in in the trial  
 
8.3. STUDY INTERVENTION C ONTRAINDICATIONS  
 
ACT intervention contraindications  
An individual who meets any of the following criteria will be excluded from being randomized to receive 
ACT during the study:  
• Currently receiving or intend ing to receive within the next few months  any pain -specific 
psychotherapy, e.g., C ognitive Behavioral T herapy , directed towards pain even if it is only a part 
of the treatment, and delivered by a psychologist or social worker  
 Duloxetine intervention contraindications  
An individual who meets any of the following criteria will be excluded from being randomized to receive 
duloxetine during the study : 
• Pregnant: If the pa rticipan t becomes pregnant during the study, duloxetine will be rapi[INVESTIGATOR_580533].  
• Currently taking any of the following:  
Duloxetine  
Lithium 
Tramadol (Ultram, Ultracet)  
St. John ’s Wort  
Prochlorperazine (Compazine)  
Thioridazine (a psychiatric medication)  
Propafenone or Flecainide  (for heart rhythm problems)  
Ciprofloxacin (Cipro, an antibiotic)  
Linezolid (Zyvox, an antibiotic)  
Methylene Blue  
Cimetidine (Tagamet, for heartburn)  
Bupropi[INVESTIGATOR_2394] (Wellbutrin) 
 
BEST Trial Protocol v 7.0 21 9/1/2023  SNRIs:  
Venlaf axine  
Milnacipran 
Duloxetine  
Sibutramine  
Atomoxetine  
Desvenlafaxine  
Levomilnacipran 
SSRIs:  
Sertraline Paroxetine  
fluoxetine  
escitalopram 
citalopram fluvoxamine  
Vortioxetine (Trintellix)  
 
Any other contraindicated SNRIs, SSRIs, and antidepressants 
 
• Reporting a current or previous  diagnosis of any of the following  
Renal dysfunction  
End-Stage Renal Failure  
Hepatic dysfunction  
• Previous allergic or other severe adverse reaction to duloxetine  or, as determined by [CONTACT_7880], 
a medicine with duloxetine cross -reactivity .  
• History of bipolar disorder, manic epi[INVESTIGATOR_1841], or suicide attempts  
• Currently breastfeeding  
 EBEM intervention contraindications
 
An individual who meets any of the following criteria will be excluded from being randomized to receive EBEM during the study:
 
• Currently receiving or intend ing to receive within the next few months  any type of manual 
therapy or exercise treatment for low -back pain from a licensed provider 
• Uncontrolled high blood pressure (≥150 systolic and/or ≥100 diastolic) 
• Uncontrolled coronary artery disease  
• Inability to walk at least 50 feet unassisted  
• Contraindication for manual therapy  
• Contraindication for participation in an exercise program 
 
ESC intervention contraindications  
An individual who becomes pregnant during the study  will be counseled to stop NSAIDs. 
8.4. PHENOTYPI[INVESTIGATOR_580534] / Venipuncture:  
• Active infection over the site of blood draw 
• Recent or recurrent history of fainting/vasovagal syncope with previous blood draws  
• Lack of vascular access (inability to find venous access)  
 
BEST Trial Protocol v 7.0 22 9/1/2023  Stool collection:   
• None  
Biomechanical Assessment:    
• Inability to walk at least 50 feet unassisted  
• Inability  to stand for at least 10  minutes  
• Participants with an allergy to adhesives will not have adhesive sensors placed on their body  
Imaging:  
• Certain implanted medical devices (e.g., implanted cardiac devices, cochlear implants, or 
intracranial aneurism clips)  
• Ferrous m etal (e.g., wire mesh, screws) in the body  that will cause safety issues  (titanium 
implants are acceptable)38  
• Waist circumference equal to or greater than the bore diameter of the study site scanner  
• Pregnancy  
QST: 
• Peripheral neuropathy  
• Participants with a history of Raynaud ’s Syndrome will not undergo cold -water immersion  
• Participants with circulatory or sensory problem  in the hands  will not undergo cold-water 
immersion 
• Participants with SBP  ≥150 and/or DBP  ≥100 will not undergo cold-water immersion 
8.5. LIFESTYLE CONSIDERAT IONS  
Not applicable 
 
8.6. SCREEN FAILURES  
Screen failures are defined as participants who consent to participate in the clinical trial but are not 
subsequently randomly assigned to the study intervention or entered in the study. A minimal set of 
screen failure information is required to ensure tra nsparent reporting of screen failure participants , to 
meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, eligibility criteria, and any serious adverse event (SAE).  
8.7. STRATEGIES FOR RECRUITMENT AND RETENTION  
 Study participants will be recruited from direct contact [CONTACT_580602], screening via electronic health 
records (EHR)  for chronic back pain, online surveys,  and through community outreach. Sites may also 
choose to compensate current participants who refer others with cLBP that enroll and remain in the 
study.  Site coordinators will generate a programmable phenotype based on the inclusion/exclu sion 
criteria to generate a list of medical record numbers/unique patients to be screened. Site coordinators 
will use electronic health records (EHR) to search for ICD10 codes indicating the presence of chronic low back pain M54.40, M54.41, M54.42, M54.5, and M54.[ADDRESS_763387] numbers/unique potential participants. Progress notes housed within the EHRs may 
also be searched by [CONTACT_580603] “low back pain,” “back pain,” or “lumbago”  in 
order to generate a list of medical record numbers/unique potential participants. Site coordinators may use additional ICD10 codes and progress note keywords as they develop and identify effective search 
 
BEST Trial Protocol v 7.0 23 9/1/[ADDRESS_763388] of unique potential partici pants  will be updated as frequently as daily such that new 
patients coming into the system with chronic low back pain or who develop chronic low back pain may 
be screened for eligibility. Patient’s records will be further screened to determine if any exclusion 
criteria are met.  Patients meeting the inclusion/exclusion criteria will be contact[CONTACT_580604]-screening call, sent a letter assessing interest in the study,  or approached during a scheduled 
clinic visit  as allowed by [CONTACT_779]’s regulatory guidelines .   
Enrollment of a diverse sample will be monitored in real time to ensure overall enrollment approximates 
the US population experiencing low -back pain.  The DAC will assess subgroup enrollment targets each 
month and instruct sites to  adjust recruitment to correct under or overrepresentation of any particular 
subgroup.    
Various approaches will be considered to enhance participant retention including scheduling flexibility, 
phone calls from the coordinators (or electronic messaging), updates on study progress (such as regular 
study newsletter targeted at the participants, celebrating milestones), and invitation to provide input 
into future studies.   Recruitment and retention throughout the study will be monitored by [CONTACT_580605], which will  oversee 
development of materials to facilitate recruitment and retention, monitor progress of both as the study progresses, and develop strategies for addressing recruitment and retention issues as they arise. The 
Data Safety and Monitoring Board ( DSMB) w ill monitor accrual at each clinical center based on periodic 
summary reports provided by [CONTACT_580606] ( see Section 14.1.8) and make recommendations 
on proposals to address recruitment or retention challenges, such as adding clinical centers, i f needed.  
9. PHENOTYPIC ASSESSMEN TS 
 
Phenotypic assessments will take place during the study.  Some assessments will be required in order for inclusion in the study, therefore, individuals who are contraindicated to any of the required phenotypic assessments will not be eligible for study participation.  All participants in the study will be required to 
answer questionnaires, receive a physical assessment , receive a motion assessment lasting 
approximately [ADDRESS_763389] of enrolled participants will opt to undergo these additional assessments.  This subset of participants will, in addition to the required assessments, receive motion assessments lasting approximately 40 minutes at each of 3 separate visits, be asked to wear an actigraphy sensor at home 
continuously for 7 days, receive an advanced spi[INVESTIGATOR_580535] 30 minutes, receive a 
brain MRI lasting approximately 60 minutes at each of 3 separate visits, and receive Quantitative 
Sensory Testing lasting approximately 60 minutes at each of 3 separate visits. Total patient time for additional phenotypi[INVESTIGATOR_465932] 4 hours and 40 minutes  at the baseline visit, and approximately 
3 hours and 40 minutes  at the 12 - and 24 -week visits.  
 
Required Phenotypic Assessments  Optional Additional Phenotypic Assessments  
20-minure motion assessment at 3 time points  60-minute motion assessment at 3 time points  
60-minute basic spi[INVESTIGATOR_580536] 1 time point  7-day continuous at -home activity monitoring via a wearable sensor  
Questionnaires/PROs  30-minute advance d spi[INVESTIGATOR_580536] [ADDRESS_763390] Trial Protocol v 7.0 24 9/1/[ADDRESS_763391] is included in Section 16.    
9.2. BLOOD DRAW / VENIPUN CTURE  
All participants will undergo the following blood draws at Baseline (Visit 0) and the 12 - and 24 -week 
visits (Visits 1 and 2), with the exception of the PAXgene DNA tube which will be collected only at the 
Baseline visit.  At each visit, approximately 32mL  of blood will be drawn and collected in the following 
tubes:  
• 1 TruCulture tube  
• 1 Sodium Heparin tube  
• 1 EDTA tube  
• 1 PAXgene DNA tube  
• 3 PAXgene RNA tubes 
Blood samples will be minimally processed per protocol at the study site and stored until such 
time as they are shipped to the NYU Langone Health Center for Biospecimen Research and 
Development (CBRD).  Batch sample shipments will occur at a frequency specified by [CONTACT_580607] C.  
 
During the study period, Cytokines/MMP, TruCulture, and Genome-wide association study (GWAS) 
analyses will be conducted on the study samples.  Blood samples collected in the Sodium Hep arin tube 
and PAXgene RNA tubes will be stored for possible future analyses. 
At the end of the study,  the CBRD will ship all remaining samples to the repository(ies) approved by [CONTACT_4289] . 
9.3. STOOL COLLECTION  
Study sites will provide participants with stool collection kits to be used at home.  A pre- paid shippi[INVESTIGATOR_580537].  Participants will be instructed to return their stool sample to t he 
CBRD where the sample will be stored for possible future analyses.  
At the end of the study,  the CBRD will ship all remaining samples to the repository(ies) approved by [CONTACT_4289].  
9.4. BIOMECHANICAL ASSESSMENT  
All participants will undergo a single biomechanical a ssessment at Baseline (Visit 0) and the 12 - and 24 -
week visits (Visits 1 and 2).  At each visit, sensors will be placed on the participant’s pelvis and chest, and 
the participant will be asked to complete a series of motions.  Data from these motions will be uploaded 
from the sensors to the cloud.  This biomechanical assessment requires approximately [ADDRESS_763392] Trial Protocol v 7.0 25 9/1/2023  Study participants who participate in the additional  phenotypic assessments will undergo three 
additional biomechanical assessments at Baseline (Visit 0) and the 12 - and 24 -week visits (Visits 1 and 
2).  These additional assessments require proprietary sensors be placed on the skin of the participants' 
back, waist, and/or hip using adhesive tape, and the participant will be asked to complete a short series 
of motions that include several repetitions of bending, side bending, and twisting as far as remains 
comfortable. Participants will also be asked to complete a series of repeated sit -to-stand 
maneuvers.  Manual palpation of the participant’s spi[INVESTIGATOR_580538].  Additionally, some of these same motions will be performed in front of a 3D depth 
camera.  Data from these motions will be uploaded from these sensors to a secure location on the cloud  
before being securely transferred to the BACPAC Data Portal under the guidelines outlined in the BACPAC Data Portal Transfer Standard Operating Procedures ( SOP).  The complete s et of these 
additional biomechanical assessments will require approximately 50 to 60  minutes of patient time . 
Study participants who participate in  the additional phenotypic assessments will also be provided with 
actigraphy sensors to be worn continuously for 7 days at home.  At the end of the 7 -day assessment, 
participants will return the sensor to the clinic using the pre -paid label provided.  Data from the sensors 
will be uploaded to a secure location. 
9.5. IMAGING  
 All participants will undergo a single MRI  of their lumbar spi[INVESTIGATOR_580539] (Visit 0).  This scan requires 
approximately 30 minutes of patient time. The following pulse sequences are required:  
• Sagittal T2 -weighted with fatsat (SAG T2 fs)  
• Sagittal T1 -weighted without  fatsat (SAG T1)  
• Axial T2 -weighted without fatsat (AX T2)  
• Axial T1 -weighted without fatsat (AX T1)  
• Coronal T1 -weighted without fatsat covering both SI joints (COR T1)  
• Sagittal T1 -weighted without fatsat for SI joints (SAG T1)  
 Study participants who participate in  the additional  phenotypic assessments may  undergo  an advanced 
MRI scan of their spi[INVESTIGATOR_580539] (Visit 0). This scan requires approximately 30 minutes of patient time 
in addition to the required scan, for a total of approximately 60 minutes of patient time. The following pulse sequences will be collected on as many participants as is possible given individual site technology:  
• MR spectroscopy  
 Study participants who participate in the additional  phenotypic assessments will undergo an MRI of 
their brain at Base line (Visit 0) and the 12 - and 24 -week visits (Visits 1 and 2). This scan requires 
approximately 60 minutes of patient time. The following scans are required:  
• Tri-Planar Scout  
• 3D MP -RAGE  
• Resting State  
• Diffusion Tensor Imaging  
 Imaging Data  
 DICOM images will be transferred to the BACPAC Data Portal to allow radiologists or others to analyze centrally. Personally identifiable information will be removed from all images prior to uploading the 
 
BEST Trial Protocol v 7.0 26 9/1/2023  image to XNAT.  Stored images will contain only the participant I D, the date of the image, and the scan 
type.  
 
Spi[INVESTIGATOR_580540] a central reading center where 
they will be processed for tissue segmentation and measurement prior to the DICOM images being transmitted b ack to the BACPAC Data Portal.  
 
Advanced Spi[INVESTIGATOR_344497] (i.e., MR spectroscopy acquisitions ) will be transmitted securely from the UNC 
secure OneDrive to a commercial entity where they will be processed.  The resulting reports will then be 
transmitted back to the UNC secure OneDrive . 
 
Scanning a test subject prior to implementing imaging protocols is optional.  Sites choosing to scan a test 
subject must meet their local IRB requirements.  Test subject data will not be included as part of trial 
data.  
 
9.6. QUANTITATIVE SENSORY TESTING  
 Study  participants who participate in  the additional  phenotypic assessments will undergo quantitative 
sensory testing, which is comprised of the three components below.  QST requires approximately 60 minutes of patient time.    
 Pressure pain sensitivity   
Pressure pain sensitivity will be assessed using an analog  algometer with a 1 -cm
2 rubber probe 
(FPK25 , Wagner Instruments, Greenwich, CT, [LOCATION_003]) to quantify pressure pain thresholds 
(PPT).   The primary  test site will be located in the lumbar region by [CONTACT_2299]’s response to 
manual over -pressure (springing palpation) performed in the prone position.   The control site 
will be located over the contralateral trapezius muscle (diagonal from lumbar  site).   Pressure will 
be manua lly increased at a rate of  rise of  0.5 kgf/cm2/s (10 kg max, metronome guided) until 
participants  first report  that the pressure  sensation  becomes  painful.  Pressure intensity 
(in kgf/cm2) read from the  algometer at that time  is considered the PPT.   Measur ements will be 
conducted 3x/site with [ADDRESS_763393] 
the progressive increase in dorsal horn neuronal firing in response to repetitive C -fiber 
stimulation.
39-41 Enhanced temporal summation is common in chronic pain and is predictive of 
pain outcomes .43,44 We will evaluate temporal summation using a 
40g Neuropen  Neurotip (Owen Mumford,  Oxfordshire, [LOCATION_008]) applied to the  skin of 
volar forearm and lumbar region , follow ing a train of 10 identical stimuli (1 Hz)  using a 
metronome for timing. P articipants will report retrospectively the pain intensity of the 1st and 
10th pi[INVESTIGATOR_580541] a 0-10 numerical rating scale  (NRS; 0 = no pain,  10 =  worst  imaginable  
pain ).  The palmer forearm and lumbar regio n will each be tested three times.   Temporal 
summation for each site will be calculated as the mean difference in pain ratings of the 1st and 
 
BEST Trial Protocol v 7.0 27 9/1/2023  10th stimulus.   Participants will also rate any ongoing  pain aftersensations  at 15- and 30 -
s following each  train  of stimuli.    
 
Conditioned  Pain  Modulation   
Immersion of one hand  (ipsilateral to the primary lumbar pain site)  into a circulating cold -water 
bath ( 10°C; NESLAB Digital One RTE 7, Thermo Scientific, Newington, NH, [LOCATION_003], or similar) will 
serve as the conditioning-stimulus and PPT at the contralateral trapezius will serve as the test -
stimulus.  This method is consistent with that of Locke45and others.46,[ADDRESS_763394]-stimulus will be acquired during the assessment of pressure pain sensitivity (see above).  Conditioning stimulation will begin by [CONTACT_580608] a level approximately [ADDRESS_763395] into the water bath.  The hand will be immersed for 60 -s; perceived pain of 
the water will be rated at 30 -s after hand immersion, and at 60 -s after hand immersion, or 
immediately at hand withdrawal, using a 0 -10 NRS to determine the adequacy of conditioning 
pain.
48  Trapezius PPT w ill re-measured 3x after  the hand is withdrawn from  the cold water.  
CPM magnitude will be calculated as the difference in mean PPT measured prior to and during the conditioning stimulus, with increases in PPT during conditioning interpreted as evidence of  
efficient endogenous pain inhibition
. 
 
10. STUDY INTERVENTIONS 
 
10.1.  STUDY INTERVENTION (S) ADMINISTRATION : ACCEPTANCE COMMITM ENT THERAPY  
 
10.1.1.  STUDY INTERVENTION DESCRIPTION  
ACT is a process-based therapy that is among the third -wave cognitive behavioral therapi[INVESTIGATOR_014]. It is well 
established for the treatment of chronic pain .7-[ADDRESS_763396] seeks to help individuals produce more successful responses to symptoms that are aligned with their values and goals. The 6 core therapeutic processes are acceptance (embracing unwanted experiences), cognitive diffusion  (differentiating between thoughts and experience), present -focused  attention, self -
as-context (distinguishing between observations and the observer), values, and committed action (choosing action based on values). These processes are summarized as ‘open, aware and engaged’ behavior .
[ADDRESS_763397] will take part in 12 sessions over the course of a 12 -week treatment 
period (Section 10. 1.2). There will be a combination of [ADDRESS_763398]-supported online sessions (self -directed online modules plus provider coaching via an online 
messaging system). Qualifying thera pi[INVESTIGATOR_580542]. Section 10.1.[ADDRESS_763399] Trial Protocol v 7.0 28 9/1/[ADDRESS_763400] of a combination of text, 
audio and video content. In-session exercises are intended to build psychological flexibility and skills in 
the 6 core therapeutic processes  (acceptance, cognitive diffusion, present -focused attention, self-as-
context, values, and committed action). After each online session, participant responses are sent to the therapi[INVESTIGATOR_580543]. All remote face-to -face 
therapy visits will take place virtually via a HIPAA -compliant platform such as Zoom. Access to the online 
content will require log -in via a personal account established at Visit 0.  
Participants are encouraged to practice skills at home daily, repeating exercises from that week’s session 
(as well as th ose from previous weeks) and to record their progress in a daily diary. Participants provide 
feedback by [CONTACT_580609][INVESTIGATOR_580544]. The platform includes a n internal messaging service that allows 
for provider coaching throughout the week. This allows for enhanced engagement in the ACT treatment. 
The digital platform will also track progress on Openness, Awareness, and Committed Action for 
participants and pr oviders. Depending on a participant’s progress in these three areas, the provider may 
recommend additional supplemental content as detailed in an ACT manual.  
ACT Protocols for the Second Treatment Period  
Participants who are initially randomized to ACT, d epending on their response to treatment, will be 
assigned to either i) maintain ACT, ii) be randomized to ACT plus an augmentation therapy or iii) be 
switched to another treatment for the second treatment period. Participants assigned to maintain ACT (with  or without a second augmentation treatment) will be encouraged to continue at -home skills and 
will have access to all previously viewed online content. In addition, participants will have access to [ADDRESS_763401] content.  
10.1.2.  DOSING AND ADMINISTR ATION  
 
Week  Session Type  Activity  
1 Remote face -to-face Visit 1 : Introduction Familiarize with online treatment  
[ADDRESS_763402] -supported online  Session 1: Shift Your Focus and What Will you Do?  
 
BEST Trial Protocol v 7.0 29 9/1/[ADDRESS_763403] -supported online  Session 2: Drop the Struggle and Act with Openness  
3 Remote face -to-face Visit  2: Review workbook,  skills, goals; identify barriers  
[ADDRESS_763404] -supported online  Session 3: Act with Openness to Thoughts  
[ADDRESS_763405] -supported online  Session 4: Clarify Your Values, Define Your Goals, and Act  
[ADDRESS_763406] -supported online  Session 5: Focus on the Present Moment and Take Action  
[ADDRESS_763407] -supported online  Session 6: Build Further Engagement and Incorporate Barriers   
5 Remote face -to-face Visit 3: Review workbook, skills, goals; identify barriers  
[ADDRESS_763408] -supported online  Session  7: Commit, Act, and See You’re the Observer -Self 
[ADDRESS_763409] -supported online  Session 8: Build Wider Patterns of Success  
7 Remote face -to-face Visit 4: Review workbook, skills, goals; close out treatment  
 
Delivery of the online content is standardized given that all participants will view the same content, 
delivered in the same order to all participants. Delivery of the intervention by [CONTACT_2111][INVESTIGATOR_580545]. Therapi[INVESTIGATOR_169370] a detailed manual covering the goals of the face -to-face sessions (in 
addition to online content) as well as a checklist for activities that should take place at each session. In 
addition, they will receive centralized training and certification, with periodic re -training, and will 
complete self -assessments. A 5 % random sample of telehealth sessions per provider will be recorded 
and reviewed and evaluated for adherence and fidelity. At least once per month, and with greater 
frequency at the beginning of the study, all providers will meet with the central ACT provider who will support fidelity and competency in an effort to prevent drift.  
10.1.3.  ACQUISITION AND A CCOUNTABILITY 
The ACT online platform will be HIPAA and FISMA compliant and will be hosted centrally on a University of North Carolina server. Participants assign ed to ACT will have secure logins  and passwords to access 
the site.  
10.1.4.  STUDY INTERVENTION C OMPLIANCE  
 
BEST Trial Protocol v 7.0 30 9/1/2023  Adherence to the intervention will be assessed in terms of 1) attendance at each remote face -to-face 
session, 2) access and completion of each online module, 3) completion of exercises as recorded in the 
online platform, and 4) days of at -home skills practice as measured with the online workbook. 
Compliance with ACT treatment is defined as completion of at least half of the prescribed visits and 
modules. Participants completing fewer than 2 face-to -face visits or fewer than 4 online modules will be 
consider ed non -compliant.  
10.2.  STUDY INTERVENTION(S) ADMINISTRATION: DULOXETINE  
Duloxetine hydrochloride is a selective serotonin and norepi[INVESTIGATOR_26331] (SSNRI) for oral 
administration. Its chemical designation is (+) -(S)-N- methyl -γ-(1-naphthyloxy) -2-th iophenepropylamine 
hydrochloride. The empi[INVESTIGATOR_24598] C18H19NOS0 -HCl, which corresponds to a molecular weight of 
333.88. Duloxetine hydrochloride is a white to slightly brownish white solid, which is slightly soluble in water.  
Duloxetine is a serotonin norepi[INVESTIGATOR_26331] (SNRI) that is FDA-approved for use in cLBP  and, as such, is included as a recommended therapy in nearly all current treatment guidelines for low-back pain and was selected by [CONTACT_580610]- based intervention to be 
included in this precision medicine study. Duloxetine and other drugs that increase both serotonergic and noradrenergic activity (e.g. tricyclics) are thought to work as analgesics by [CONTACT_580611] -nociceptive pathways.
13 There will not be a placebo arm for this intervention as 
this study is designed to optimize a precision medicine algorithm as opposed to investigate the effectiveness of duloxetine versus a placebo. 
10.2.1.  DOSING AND ADMINISTR ATION  
Duloxetine  is a selective serotonin and norepi[INVESTIGATOR_26331] (SSNRI) for oral 
administration. Its chemical designation is (+) -(S)-N- methyl -γ-(1-naphthyloxy) -2-thiophenepropylamine 
hydrochloride. The empi[INVESTIGATOR_24598] C18H19NOS0 -HCl, which c orresponds to a molecular weight of 
333.88. Duloxetine hydrochloride is a white to slightly brownish white solid, which is slightly soluble in water.  
Each capsule contains enteric-coated pellets of 33.7 mg of duloxetine hydrochloride equivalent to 30 mg of duloxetine. These enteric -coated pellets are designed to prevent degradation of the drug in the acidic 
environment of the stomach. Inactive ingredients include FD&C Blue No. 2, gelatin, hypromellose, hydroxypropyl methylcellulose acetate succinate, sodium  lauryl sulfate, sucrose, sugar spheres, talc, 
titanium dioxide, and triethyl citrate.  
Participants randomized to the duloxetine arm will review the dosing schedule for the medication and 
safety information for the medication at the baseline visit with the study coordinator. At the baseline 
visit a physical assessment  will be performed. Certain sections must be completed by a licensed medical 
professional (e.g., MD, DO, FNP, PA, PT ). Drug contraindications (including allergy to duloxetine, 
concomitant anti depressant use, concomitant tramadol use, liver disease, kidney disease, concomitant 
of St. John’s  wort use) will be reviewed with the participan t. Pa rticipants reporting a history of bipolar 
disorder, manic epi[INVESTIGATOR_1841], or suicide attempts  will not be randomized to the duloxetine intervention 
arm. Participants will also be counseled on seeking emergency help if suicidal ideation occurs while on 
duloxetine.   
 
BEST Trial Protocol v 7.0 31 9/1/[ADDRESS_763410] an assessment via phone on day 7 (or next business day if falls on a weekend) of the intervention phase with participants newly randomized to d uloxetine (i.e., day [ADDRESS_763411] or 
second intervention period). Study staff will document in the case response forms any adverse events and safety concerns the participants may have.  
At the Day 7 assessment: 
Participants tolerating the medication with no side effects (e.g. nausea) will be escalated to 60 mg (two 
30 mg capsules) by [CONTACT_580612].  
Participants tolerating the medication with mild side effects  will have the option to stay at [ADDRESS_763412] period intervention will be instructed to discontinue treatment until the next randomization 
point (Visit 1) at which time they will be randomized to a non- duloxetine second period intervention. 
Participants randomized to duloxetine in the second period intervention and not tolerating the 
medication  will be instructed to discontinue duloxetine until their final follow -up of outcomes [ADDRESS_763413] baseline (Visit 2 ). 
All participants will be provided with the site phone number and instructed to call if they have new or worsening side effects. If any safety or adverse eve nts occur, the medication will be discontinued.  
All participants will be assessed at the midpoint of the intervention treatment period (i.e., either Week 6 
or Week 18) for tolerance, adverse events, and response. At the midpoint phone call : 
Participants tolerating the medication with no side effects will be instructed to increase to 60mg/day (if 
currently taking 30mg/day) or remain on their current dosage (if currently taking 60mg/day) . 
Participants tolerating the medication with mild side effects (e.g. nausea)  will be given the option of 
continuing their current dosage (30mg/day or 60mg/day), reducing their dosage (from 60mg/day to 30mg/day), or tapering off their current dosage (if currently taking 30mg/day).  
Participants not tolerating the medication  will be instructed to taper off the medication.  
During the Week 18 cal l, participant s will be reminded that their study treatment period is ending in six 
weeks.  If they are tolerating the study medication and would like to continue duloxetine after the end 
of the treatment period, they should schedule an appointment with their provider to discuss continuing 
their duloxetine treatment outside of the study , in order to avoid a lapse in medication . 
Tapering instructions : 
The standard tapering period is up to two weeks.   The following instructions will be provided to 
participants when they end their duloxetine treatment at either Visit [ADDRESS_763414] Trial Protocol v 7.0 32 9/1/[ADDRESS_763415] dose no later than 21 days after 
Visit 1 or 2.  
10.2.2.  ACQUISITION AND A CCOUNTABILITY 
Site staff will be responsible for ensuring study participants are instructed on how to return study 
medications and for tracking returned medication.  
When medication is returned, site staff will count how many capsules are left and this number will be 
reported on the drug accountability log, and the remaining capsules will be disposed according to local, institutional policy.  
  
10.2.3.  FORMULATION, APPEARANCE, PACKAGING, AND L ABELING  
Duloxetine hydrochloride is a selective serotonin and norepi[INVESTIGATOR_26331] (SSNRI) for oral 
administration. Its chemical designation is (+) -(S)-N- methyl -γ-(1-naphthyloxy) -2-thiophenepropylamine 
hydrochloride. The empi[INVESTIGATOR_24598] C18H19NOS0 -HCl, which corresponds to a molecular weight of 
333.88. Duloxetine hydrochloride is a white to slightly brownish white solid, which is slightly soluble in water.   
10.2.4.  PRODUCT STORAGE AND S TABILITY 
Medications will be procured from the approved  drug pharmacy at each site to retain a supply to recruit 
at least [ADDRESS_763416] be managed between 20 -25
oc (68 -77oF); excursions permitted to 15 -30oC (59 -86oF) – per package insert. Medications may a lso be 
mailed to participant directly in the event of dispensing challenges (for example as related to the COVID pandemic).  Sites must follow the guidelines outlined the Duloxetine Pharmacy Manual for
 mailing the 
study medication.  
10.2.5.  PREPARATION  
30 mg capsul e 
10.2.6.  STUDY INTERVENTION C OMPLIANCE  
Compliance with study protocol will be assessed by [CONTACT_580613][INVESTIGATOR_692]. P articipants will be 
required to return remaining medications to the study site at the time of their next in- clinic study visit 
(Visit 1 o r Visit 2) .  Unused pi[INVESTIGATOR_580546].  At sites 
that mail the study medication  directly to participants , these participants may be permitted to retain 
medication previously dispensed during Visit [ADDRESS_763417] Trial Protocol v 7.0 33 9/1/2023  Adherence to the int ervention will be assessed in terms of 1) missed doses as reported by [CONTACT_25955] 2) number of capsules left in the returned medication bottle.  
10.3.  STUDY INTERVENTION(S ) ADMINISTRATION: E NHANCED SELF-CARE  
The content of the Enhanced Self -Care interven tion is based on interventions which are currently 
available as part of many clinical practices but is formatted and structured in a manner that will provide 
multiple modules over the intervention period.  The intervention is considered ‘enhanced’ in that most 
individuals with chronic pain do not receive an educational and self -care package.  It is self -care given 
there will be no therapi[INVESTIGATOR_580547]. The intervention 
will be provided digitally via multiple modules for self -administration over a period of [ADDRESS_763418] of evidence -based cognitive-behavioral self -management skills for pain.  While all 
content is available to participants at all times, automated weekly email or text messag ing will guide 
participants to specific content. Much of the material is derived from the current University of Michigan 
online self -management program called PainGuide.      
PainGuide (https://PainGuide.com ) is an educational website promoting the use of cognitive and 
behavioral self -management skills for chronic pain that is accessible online or by [CONTACT_10753]. PainGuide 
offers (A) education about pain, pain mechanisms, types of pain including chronic overla ppi[INVESTIGATOR_580548] (COPCs), and education about a wide variety of professionally administered pain treatments, (B) rationale and resources for using a variety of self -management approaches for pain, (C) a system for 
monitoring symptoms and self -management activities and (D) external resources supporting pain self -
management .
54-57 Multi -media is used in communicating content including videos, text, audio files, apps, 
and downloadable worksheets. PainGuide is an expanded version of its predecessor FibroGui de, a 
similar digital pain self -management program with efficacy supported by [CONTACT_260543].58  For the 
purposes of the proposed study, PainGuide has been adapted to the needs of patients with chronic low -
back pain.   
The Enhanced Self Care intervention arm will be comprised of three major components delivered via a single platform : 
• Behavioral Self -Management – Established education and cognitive -behavior based self -
management skills training and symptoms monitoring.  
• Walking Program – a new module cont ained within PainGuide that offers a structured walking 
program that uses Fitbit devices for monitoring walking (e.g., Steps).  
• Personalization and Engagement – ESC uses weekly automated email or text messaging to 
encourage engagement and to personalize th e self -management content to be highlighted each 
week based upon participants’ baseline surveys.  
For this study, a customized version of PainGuide will be used. This version of the self -management 
website will include curated education and content targete d to a chronic low -back pain population. Two 
new  modules have been added: a Walking Program utilizing Fitbit activity trackers for feedback and an 
over-the -counter (OTC) treatment module (e.g., NSAIDs and topi[INVESTIGATOR_39671]). The walking program 
will utilize Fitbit step tracking to allow participants to monitor their walking progress, while the OTC medication content will be educational in nature.  
10.3.1.  DOSING AND ADMINISTR ATION  
 
BEST Trial Protocol v 7.0 34 9/1/[ADDRESS_763419] participants to watch the overview sections on chronic low- back  pain and the rationale for self -management of pain (E ducation). 
Study participants will be instructed to use this program for a period of [ADDRESS_763420] few modules in a prescribed order: (1) Educational 
sections (“What is Pain” “Pain Mechanisms”, and “Approaches to Pain Management,” (2) Goal setting, (3) the Fitbit Walking program, and (4) OTC analgesics.  
After the first four modules, email or text messages will be used to make personalized recommendations for accessing additional modules based upon identified problems from the baseline assessment  using the PROMIS -29+[ADDRESS_763421] of t he PainGuide modules focus on self -care, education and aerobic exercise (walking program).  
The PainGuide’s educational module on medication has been adapted for BEST  to provide a more 
detailed discussion of the use of self -administered over -the-counter (O TC) medications for chronic low-
back pain.  The medication module focus es on NSAIDs, which have been demonstrated to be an 
effective intervention in numerous cLBP trials and systematic reviews. Most of the discussion will be on NSAID oral medications such as ibuprofen and naproxen and the importance of consistent dosing. However, these medications are not tolerated by [CONTACT_580614], and oral NSAIDs are contra -indicated 
for some cLBP patients, such as those with a history of gastrointestinal bleeding or wh o take oral anti -
coagulants.  Materials will stress the importance of the participant talking with their primary care or pain management provider in such circumstances.  The module will also provide information on other OTC preparations such as oral acetam inophen, topi[INVESTIGATOR_580549].   
The BEST trial’s  walking program module will build on PainGuide’s pacing and self -care modules. 
Specifically, this module will provide guidance on the importance of aerobic exercise for cLBP as well as specific self -monitoring, goal -setting, and problem-solving education appropriate for cLBP patients. The 
module will provide strategies to counter maladaptive pain beliefs, especially fear avoidance regarding 
movement. All participants will be given a web-co nnected wearable device, Fitbit, to assist in monitoring 
their step count (a metric of functional status).  
Participants will continue to have access to all of PainGuide modules throughout the trial. Use of the 
website will be captured passively with website utilization metrics. The online platform will also provide the participants tools to track their symptoms.  
The Enhanced Self Care arm will be delivered via online self -management modules : 
• Week 1:  Educational content  
o What is Pain  
o Pain Mechanisms  
o Approaches to Pain Management  
• Week 2: Goal setting  
• Week 3: Fitbit walking program 
• Week 4: OTC analgesics  
 
BEST Trial Protocol v 7.0 35 9/1/2023  • Weeks 5 -12: Personalized recommendations (based on baseline, e.g., PROMIS 29+2, modules: 
(e.g., Sleep, Mood, Reframing)  
 
ESC Protocol for Second Randomization Period  
Participants randomized to continue receiving ESC in the second period intervention will receive 
personalized recommendations based on the most recently completed PROMIS 29+2.  
10.3.2.  ACQUISITION AND A CCOUNTABILITY 
PainGuide is hosted central ly on a University of Michigan Server . Study staff at each participating site 
will be given the ability to establish personal accounts for each participant who is randomized to the ESC arm of the study.  
10.3.3.  STUDY INTERVENTION C OMPLIANCE  
Adherence to the interv ention will be assessed in terms of 1) which modules were accessed by [CONTACT_580615], 2) how long the participant spent on each module, 3) a questionnaire asking participants to provide feedback on their experien ce with the 
materials , and 4) number of days with login/activity . 
10.4.  STUDY INTERVENTION(S ) ADMINISTRATION: E VIDENCE -BASED EXERCISE AND 
MANUAL T HERAPY  
Evidence -Based Exercise and Manual Therapy (EBEM) is provided by a licensed physical therapi[INVESTIGATOR_580550] . Evidence-based guidelines , including those from the American College of 
Physicians, the Agency for Healthcare Research and Quality, and the Departments of Defense and Veterans’ Affairs, indicate that exercise and manual therapy are beneficial for persons with chronic back 
pain. Practice Guidelines and Systematic Reviews support benefits of exercise and manual therapy for persons with chronic LBP.
59,[ADDRESS_763422] suited to an individual study participant. Special attention is paid to the clinician’s choice of language in regard to the purpose and expected outcomes of manual therapy in order to avoid enhancing catas trophizing ideations or preference for 
passive interventions.  
 
BEST Trial Protocol v 7.0 36 9/1/[ADDRESS_763423] ic to personalize 
care to individual participants and enhance their effectiveness. These strategies are outlined below:  
Risk Stratification  
Risk stratification involves identifying physical and psychological factors associated with developi[INVESTIGATOR_580551].  The type and dosage of the EBEM treatment components (exercise, manual 
therapy and education) will be based on the participant’s degree of risk. Training will provide guidance on how each of the treatment components can be tailored to participant’s risk based on the results of the STarT Back Screening Tool  collected at the baseline visit . 
Intervention Tailoring  
The core components of EBEM (exercise and manual therapy) will be tailored to address the unique needs of an individual participant. Training will  focus on Treatment-Based Classification (TBC) as a 
decision-making framework with evidence to support its effectiveness. The TBC decision -making 
framework trains clinicians to tailor the particular selection of exercise and manual therapy techniques to individual patients with back pain.  
Education Strategies  
All participants will be helped to understand the biopsychosocial model of pain, which places 
emphasis on the important role of thoughts and attitudes as well as environmental factors on the 
pain experience. Key messages include the importance of remaining active and maintaining a positive outlook towards recovery. Education strategies are also designed to enhance participants’ self-efficacy through motivation-enhancing communication and shared -goal se tting procedures. 
Training will emphasize recommended communication strategies for establishing an optimal supportive and collaborative relationship with participants.   
10.4.1.  DOSING AND ADMINISTR ATION  
The EBEM intervention will be provided in face- to-face, one -on-one, sessions with a licensed physical 
therapi[INVESTIGATOR_580552]. A total of [ADDRESS_763424] two weeks followed by [CONTACT_580616] 6 weeks . If visits are missed and/or need to be 
rescheduled, visits may be scheduled for up to [ADDRESS_763425] their intervention visits monitored for fidelity via a video recording or in-person observation once they are certified to deliver the intervention.  Fidelity assessments will be 
conducted with greater frequency during the early stages of enrollment and then as needed. Video 
recordings/observations will be reviewed/performed by [CONTACT_580617] v 7.0 37 9/1/[ADDRESS_763426]. Fidelity assessments will focus on verifying that the exercise and manual 
therapy components were delivered as outlined in the protocol, and that no prohibited interventions 
were delivered. Individual providers will receive additional or remedial training in the intervention 
protocol when ever deficiencies in fidelity are observed.  
EBEM Protocol for Second Randomization Period  
Participants randomized to continue receiving EBEM in the second period intervention will receive 4 additional in -person EBEM sessions during weeks 1 -4 of this period . If visits are missed and/or need to 
be rescheduled, visits may be scheduled up to [ADDRESS_763427] 
augmenting/maintenance visit. 
10.4.2.  ACQUISITION AND A CCOUNTABILITY 
Licensed Doctors of Chiropract ic and physical therapi[INVESTIGATOR_580553]. Training will consist of a total of [ADDRESS_763428] 3 of the 4 prescribed visits  
10.4.4.  MEASURES TO MINIMIZE BIAS: RANDOMIZATION  AND BLINDING  
The first-stage randomization will use a randomized version61 of the Minimization method62,63 to 
maintain marginal covariate balance. Minimization is an alternative to stratified permuted block randomization for maintaining (marginal) covariate balance across treatments that is better  equipped to 
handle a larger number of factors to balance on. When a participant is randomized, a measure of the marginal discrepancy between treatments is calculated and the patient is randomized using a biased coin method where whichever treatment would make the discrepancy smallest has a higher probability 
and the other treatments have equal, smaller probabilities. Covariates included in minimization 
algorithm:  
• Willingness to participate in deep phenotypi[INVESTIGATOR_007]  (yes/no)  
• Depressive or anxiety symptoms (yes/no)  
• Duration of pain symptoms (<5 years/ ≥5 years)  
• Current use of opi[INVESTIGATOR_2512]  (yes/no)  
 
A total of approximately [ADDRESS_763429] ( n=18 5), duloxetine (n=18 5), ESC 
(n=18 5), and EBEM (n=18 5) and which will require recruitment of approximately 8 20 participants, 
anticipating that 10% will not be randomized due to failure to meet eligibility criteria at the end of the 
run-in phase and an estimated 15% will be lost to follow -up over the course of the study. Participants  
who did not complete required run -in procedures will not be randomized. In order to assign equal 
numbers of participants to each of the [ADDRESS_763430] Trial Protocol v 7.0 38 9/1/[ADDRESS_763431] treatment period. Response to treatment 
will be assessed using the PEG and PGIC. Based on these scores, individuals will be grouped into 4 response classes . 
• Group 1 participants (PGIC 1 -2 and PEG <4) are assigned to maintain the first -line treatment.  
• Group 2 participants (PGIC 1 -2, PEG ≥4) are assigned to maintain the current treatment and 
augment  with a randomly selected ad ditional treatment.  
• Group 3 participants (PGIC 3 -4) are randomized to an augmentation treatment or to switch to a 
new treatment.  
• Group 4 participants (PGIC 5 -7) are randomly assigned to switch to a second -line treatment.  
 
 
Table 10.[ADDRESS_763432] of  all possible augmentations (combinations of the initial treatment with a 
second study intervention) and treatment switches for each of the initial treatment assignments. This randomization will be performed within initial treatment by [CONTACT_580618]
62,[ADDRESS_763433] Stage Treatment  All Potential Second Stage 
Augmentations   All Potential Switches to Second 
Treatments  
ESC ESC + ACT  
ESC + Duloxetine  
ESC + EBEM  N/A 
ACT ESC + ACT  
ACT + Duloxetine  
ACT + EBEM  ESC 
Duloxetine  
EBEM  
Duloxetine  ESC + Duloxetine  
ACT + Duloxetine  ESC 
ACT 
 
BEST Trial Protocol v 7.0 39 9/1/[ADDRESS_763434] baseline  (Visit 1) .  
 
Randomization will be performed using the Carolina Data Acquisition and Reporting Tool (CDART), 
developed by [CONTACT_580619]. CDART is designed and implemented as a centrally hosted, web -bas ed, customizable and scalable data 
management system. Randomization algorithms will be developed by a biostatistician and custom -
written in Java, which provides a full set of libraries and tools capable of complex algorithm 
implementation. This data management system will provide a means for implementing treatment 
allocation protocols, masking allocation of future participants, and for study staff to obtain allocation information immediately following randomization. Study staff and participants will not be blinded to treatment allocation  given the nature of the interventions . Study investigators and staff involved in data 
analysis will be blinded to assignment.  
 Although patients and providers cannot be blinded with respect to study interventions, during the study 
data summaries produced for review by [CONTACT_580620]  (e.g., treatment groups randomly permuted). Unblinded summaries may be 
required for review by [CONTACT_4318]. Study team members involved  in producing DSMB reports and/or 
presenting un blinded data to the DSMB will have no role in development of the  study’s statistical 
analysis plan.  
 
11. STUDY INTERVENTION DISCONTINUATION  AND PARTICIPANT 
DISCONTINUATION/ WITHDRAWAL  
 
11.1.  DISCONTINUATION OF STUDY INTERVENTION  
 Early discontinuation of treatment is anticipated to be rare. Examples include a broken leg, precluding continuation of EBEM, or adverse reaction to duloxetine, necessitating discontinuation of duloxetine 
treatment.  
11.2.  PARTICIPANT  DISCONTINUATION /WITHDRAWAL  FROM THE S TUDY  
A participant may be discontinued from the study if he/she is shown to not meet the inclusion criteria 
based on new information that was not available at the time of initial enrollment and continuing in the study poses  a safety risk (e.g.,  pregnancy  or development of liver failure if on duloxetine) .  Participants 
should not be discontinued for reasons other than new information that constitutes a safety risk.  For 
example, if new information indicates that a participant meets one of the exclusion criteria for an 
intervention, but the criteria does not pose a safety risk to the participant, then the participant should 
not be discontinued.  In this case, the participant will be considered in violation of the protocol for t hat Duloxetine + EBEM  EBEM  
EBEM  ESC + EBEM  
ACT + EBEM  
Duloxetine + EBEM  ESC 
ACT 
Duloxetine  
 
BEST Trial Protocol v 7.0 40 9/1/2023  period and excluded from the per protocol analysis  (see Sections 10.1.4, 10.2.4, 10.3.4, and 10.4.4).  In 
general, participants with poor compliance but at no increased risk will continue in the study to 
complete all study assessments and minimize attrition.   
Other criteria for participant discontinuation at any point in the study:  
• Participant meets one or more of the safety exclusion criteria defined in Section 8.  
• Study physician determines that continuation in the study is not in the best interest of  the 
participant.  
• Participants  can withdraw consent from the protocol at any point, and that will lead to 
discontinuation from the study.  At that point, the investigator will make reasonable effort to 
ensure participant’s well -being and safety and provide a termination visit with appropriate 
documentation. 
• The site investigator may decide to stop a participant’s treatment due to side effects or other safety concerns  for the participant and/or site staff .  If the participant is participating in the 
duloxeti ne intervention arm at the time of discontinuation from the entire study, the participant 
will be advised to taper their dose as outlined in Section 10.2.  or obtain a prescription for 
duloxetine from their primary care physician or other provider.  
11.3.  LOST TO FOLLOW -UP 
Participants who do not show up for a scheduled non -intervention study  visit will be contact[CONTACT_580621] (calling, email, text). If an emergency number is provided, it can be used to contact [CONTACT_2299], at least to ensure they are doing well. P articipants who  fail to respond to voice and written 
requests to contact [CONTACT_580622] 12-Week Visit will be considered 
lost to follow -up.  Participants who miss their 24-Week Visit will not be considered lost to follow -up and 
will be sent the [ADDRESS_763435]-stage randomization  using a web -based survey platform. The primary 
endpoint is based on t he Pain, Enjoyment of Life, and General Activity (PEG) scale, a [ADDRESS_763436] week. 
Response values for each item range from 0 to 10 and the average score across the three items will be used as the outcome value . 
Secondary outcome  assessments include : 
• PROMIS Pain interference scale (PROMIS-PI, 4a)  
• Current use of opi[INVESTIGATOR_580554] a daily basis  
• PROMIS Physical Function (PROMIS -PF Short Form 6b) 
• PROMIS 4 -item Depression scale (from the PROMIS 29 profile)  
• PROMIS Emotional Distress -Anxiety scale  (PROMIS -EDA 4a)  
 
BEST Trial Protocol v 7.0 41 9/1/2023  • PROMIS Sleep disturbance (PROMIS short form 6a)  
• Sleep duration (reported number of minutes asleep per night over the past month) 
 
Primary and secondary endpoints  
• Primary endpoint: 24 -week change from baseline in patient -reported pain inten sity and 
interference , measured with the Pain, Enjoyment of Life, and General Activity (PEG) scale at 
Visits 0 (baseline) and 2 (24 weeks of treatment)  
• 24-week change from baseline in pain interference , measured with the 4 -item PROMIS Pain 
Interference scale (PROMIS -PI, 4a) at Visits 0 (baseline) and 2 (24 weeks of treatment)  
• Incidence of opi[INVESTIGATOR_2441],  measured by [CONTACT_6270] -report at Visit 2 (24 weeks of treatment)  
• 24-week change from baseline in physical function , measured with the PROMIS -PF Short Form 
6b at Visits 0 (baseline) and 2 (24 weeks of treatment)  
• 24-week change from baseline in depression score, measured with the PROMIS 4-item 
depression scale from the PROMIS 29 profile at Visits 0 (baseline) and 2 (24 weeks of treatment)  
• 24-week change from baseline in anxiety score , measured with the PROMIS Emotional Distress -
Anxiety scale (PROMIS -EDA 4a) at Visits 0 (baseline) and 2 (24 weeks of treatment)  
• 24-week change from baseline in sleep disturbance,  measured with the PROMIS short form 6a 
at Visits 0 (baseline ) and 2 (24 weeks of treatment)  
• 24-week change from baseline in sleep duration, measured at Visits 0 (baseline) and 2 (24 
weeks of treatment)  
 
12.2.  SAFETY ASSESSMENTS  
 
Participants will be screened for contraindications to any of the BEST study interventions and 
phenotypi[INVESTIGATOR_580555].  At the baseline visit, participant medical history 
will be obtained by [CONTACT_499168] a physical assessment will be performed by a qualified 
medical profess ional. Basic safety assessments will be performed at 6 weeks (midpoint o f intervention 
period one), 12 weeks (Visit 1), 18 weeks (midpoint of intervention period two), 24 weeks (Visit 2), and [ADDRESS_763437] -baseline (12 weeks after intervention period two) to assess participant tolerability to 
their current study intervention(s). Patients who are unable to tolerate their assigned study treatment will be educated on how to safely discontinue their current treatment plan but will otherwise remain in 
the study.   Study staff will conduct an  additional  assessment of participants randomized to duloxetine 
via phone on day 7 (or next business day if falls on a weekend) of the intervention phase with 
participants newly randomized to d uloxetine (i.e., day [ADDRESS_763438] or second intervention 
period).  
 
Participants will be asked to report pregnancy status at multiple time points :  prior to enrollment at Pre -
screening and Screening, and  prior to randomization at the Baseline and [ADDRESS_763439] Trial Protocol v 7.0 42 9/1/2023  12.3.1.  DEFINITION OF ADVERS E EVENTS (AE) 
An adverse event (AE) is defined as any untoward or unfavorable medical occurrence in a human patient 
or research subject, including any abnormal sign (for example, abnormal physical assessment or 
laboratory finding), symptom, or disease, temporally associated with the subject’s participation in the 
research, whether or not considered related to the subject’s participation in the research.  Adverse 
events occurring after the participant provides informed consent will be recorded.  
 
12.3.2.  DEFINITION OF SERIOU S ADVE RSE EVENTS (SAE)  
An adverse event (AE) or suspected adverse reaction is considered "serious" if, in the view of either the 
investigator or sponsor, it results in any of the following outcomes:  
• death  
• a life-threatening adverse event  
• inpatient hospi[INVESTIGATOR_059] ≥ 24 hours or prolongation of existing hospi[INVESTIGATOR_059]  
• a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or  
• a congenital anomaly/birth defect  
• Is an important medical event that may not be immediately life -threatening or result in death or 
hospi[INVESTIGATOR_580556].  
This definition permits either th e sponsor  or the investigator to decide whether an event is serious. 
Serious adverse events are critically important for the identification of significant safety problems. Therefore, if either the investigator believes that the event is serious, the event must be considered 
serious and evaluated by [CONTACT_102673] (21 CFR 312.32(a) and 312.32(c)(1)).  
 
12.3.3.  CLASSIFICATION OF AN  ADVERSE E VENT  
 
Severity of Event  
For adverse events (AEs), the following guidelines will be used to describe severity.  
• Mild – Events require minimal or no treatment and do not interfere with the participant’s daily 
activities.  
• Moderate – Events result in a low level of inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with functioning.  
• Severe – Events interrupt a participant’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually potentially life-threatening or 
incapacitating.  Of note, the term “severe” does not necessarily equate to “serious”.  
 
Relationship to study intervention  
The site investigator is responsible for assessing the relationship between the AE and the study agent(s). 
Site investigators must provide the initial assessment as to whether there is a reasonable possibility that 
the study agent(s) caused or contributed to a SAE. The relationship assessment, based on clinical 
judgment, often relies on the following:  
• A temporal relationship between the event and administration of the study agent(s),  
• A plausible biological mechanism for the agent to cause the AE,  
 
BEST Trial Protocol v 7.0 43 9/1/2023  • Another possible etiology for the AE,  
• Previous reports of similar AEs associated with the study agent or other agents in the same 
class, and  
• Recurrence of the AE after re -challenge or resolution after de -challenge, if applicable.  
Further assessment of causality is provided by [CONTACT_580623]. 
The terms used to ass ess the relationship of an event to study agent are:  
• Related – There is a reasonable possibility that the AE may be related to the study agent(s).  
• Not Related – There is not a reasonable possibility that the AE is related to the study 
agent(s).  
 
Expectedness  
Expected AEs are AEs that have been previously observed with the study intervention or procedures. An 
adverse event is considered “unexpected” if its nature, severity, or frequency is not consistent with 
either of the following:  
• the known or foreseeable risk of adverse events associated with the procedures involved in 
the research that are described in (a) the protocol -related documents, such as the IRB -
approved research protocol, any applicable investigator brochure, and the curr ent IRB -
approved informed consent document, and (b) other relevant sources of information, such as product labeling and package inserts; or  
• the expected natural progression of any underlying disease, disorder, or condition of the 
subject(s) experiencing t he adverse event and the subject’s predisposing risk factor profile 
for the adverse event.  
 
12.3.4.  TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP 
 
The occurrence of an adverse event (AE) or serious adverse event (SAE) may come to the attention of 
study personnel during study visits and interviews of a study participant presenting for medical care, or 
upon review by a study monitor. 
All AEs including local and systemic reactions not meeting the criteria for SAEs will be captured on the 
appropriate ca se report form (CRF). Information to be collected includes event description, time of 
onset, clinician’s assessment of severity, relationship to study intervention (assessed only by [CONTACT_214527] a diagnosis), and time of resolution/stabilization of the event. All AEs must be documented appropriately regardless of relationship. All AEs will be followed to adequate resolution. 
Any medical condition that is present at the time that the participant is screened will be considered  as 
baseline and not reported as an AE. However, if the study participant’s condition deteriorates at any 
time during the study, it will be recorded as an AE.  
Changes in the severity of an AE will be documented to allow an assessment of the duration of th e event 
at each level of severity to be performed. AEs characterized as intermittent require documentation of onset and duration of each epi[INVESTIGATOR_1865].  
A site physician investigator or sub -investigator will record all reportable events between the time the 
parti cipant provides informed consent through [ADDRESS_763440] Trial Protocol v 7.0 44 9/1/2023  the investigator will inquire about the occurrence of AE/SAEs since the last visit.  Events will be followed 
for outcome information until resolution ,stabiliz ation , or participant is off -study . 
 
12.3.5.  ADVERSE EVENT REPORT ING  
 
Serious Adverse Event Reporting  
Study investigators will immediately notify the DA C of any serious adverse event, whether or not 
considered test treatment -related, including those listed in the protocol or investigator brochure.  The 
report must include an assessment of whether there is a reasonable possibility that the treatment 
caused  the event.  
All serious adverse events (SAEs) will be followed until satisfactory resolution or until the site investigator deems the event to be chronic or the participant is stable. Other supporting documentation of the event may be requested by [CONTACT_941] D AC and should be provided as soon as possible.  
• All AEs will be reported in aggregate to the NIAMS and the DSMB (through the NIAMS Executive Secretary) as part of the routine DSM report.  
• All SAEs (regardless of relatedness or expectedness) will be reported to the NIAMS and the DSMB (through the NIAMS Executive Secretary) within 48 hours of the investigator becoming aware of the event.  
 
12.3.6.  REPORTING EVENT S TO PARTICIPANTS  
Participants will be informed of any adverse events or serious adverse events if risk-benefit profile is 
impacted. Events significantly impacting the study integrity will require a change in protocol and 
additionally require re-consenting of participants. All active study participants would then be notified.  
An abnormal finding may occur whenever imaging, conducting assessments, performing interventions, or completing study tasks. The purpose of imaging, assessments, and interventions are for research purposes only and are not intended to be used for clinical care (i.e., images will not be read by a 
radiologist). The imaging will not be read for clinical purposes and will not be reported to the patient 
(e.g., findings of spi[INVESTIGATOR_16078], neuroforaminal stenosis, lipomatosis, arachnoiditis will not be reported to the patient as the purpose is not for clinical care ). During the course of the study , any gross abnormal 
finding noted in imaging or other assessment may be disclosed to the participant by [CONTACT_580624] -up with their Primary Care Physician (PCP). If the patient does 
not have a primary care provider, they will be instructed to establish care with a PCP to discuss further clinical management of the abnormal finding.  Site i nvestigators will work with DAC staff to notify 
participants and ensure that the patients are informed to follow -up with their PCP. 
Examples of findings of clear clinical significance include:  
• Abnormal blood pressure  
• Intracranial abnormalities (e.g., hema toma, tumor)  
• Intraspi[INVESTIGATOR_512808] (e.g., intraspi[INVESTIGATOR_158314]) 
• Syncope during blood draws  
• Pathological reflexes  
Any other condition/finding in the discretion of the investigator that needs to be reported to the patient and assessed by a clinician/PCP.  
 
BEST Trial Protocol v 7.0 45 9/1/2023   
12.4.  UNANTICIPATED PROBLE MS 
 
12.4.1.  DEFINITION OF U NANTICIPATED PROBLEMS (UP)  
 
Unanticipated Problem Involving Risk to Participants or Others (UPI[INVESTIGATOR_9961]):  Any incident, experience, or 
outcome that:  
Is unexpected (in terms of nature, severity, or frequency) given (a) the research procedures that are 
described in the protocol -related documents, such as the IRB -approved research protocol and informed 
consent document; and (b) the characteristics of the participant population being studied;  
Is related or possibly related to a participant’s participation in the research; and  
Is serious or suggests that the research places participants or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or recognized.  
 
12.4.2.  UNANTICIPATED PROBLEM REPORTING  
 
The investigator will report unanticipated problems (UPs) to the reviewing IRB, as required,  and to the 
DAC . The UP will be entered into the DMS and will include the following information:  
A detailed description of the event, incident, experience, or outcome;  
An explanation of the basis for determining that the event, incident, experience, or outcome represents 
an UP;  
A description of any changes to the protocol or other corrective actions that have been taken or are proposed  in response to the U P.  
All UPs will be reported to the NIAMS and the DSMB (through the NIAMS Executive Secretary) within 48 
hours of the investigator becoming aware of the event.  
13. STATISTICAL CONSIDER ATIONS   
 
13.1.  STATISTICAL HYPOTHES ES 
 The general  objective of this study  is to inform a precision medicine approach to cLBP. The statistical 
focus is on the estimation of a dynamic treatment regime (DTR) rather than to  test the overall 
effectiveness of any single intervention or combination of interventions. The DTR will be estimated after 
the trial is completed, and  it will use a panel of features , i.e. phenotypic markers,  collected at baseline to 
recommend a first -line treatment, and then , depending on the response to treatment and  any changes 
in participant  covariates, recommend a second treatment (which may be a continuation of the first -line 
treatment ). The performance will be measured by [CONTACT_580625] a given outcome 
(i.e. the PEG for the primary analysis ) after two stages of treatment relative to baseline if the DTR were 
used to select treatments (called the value of the DTR). It is important to note that this goal 
 
BEST Trial Protocol v 7.0 46 9/1/2023  encapsulates discovering phenotypic markers that are associated with improved treatment resp onse 
because the outcome is a function of the treatment received and a participant’s covariates.  
This section is intended to give an overview of the estimation targets for each study objective for the 
primary efficacy endpoint : the 24-week change  from baseline in the PEG composite score. The PEG is a 
three -item scale with each item rated on a 0 -10 scale. The mean response on these items will be used as 
the outcome.  
The primary objective  is to estimate an algorithm to assign sequences of two cLBP treatments based on 
phenotypic markers and an individual patient’s response to the initial treatment (i.e.,  a dynamic 
treatment regime) that optimizes effectiveness. 
 
The goal is to estimate a DTR that maximizes the expected improvement in PEG after two stages of treatment relative to baseline. The estimation targets for this goal are 1) the parameters of the DTR and 2) the value of the estimated DTR.  
 
To s
pecify this formally, we will introduce notation from precision medicine (for a detailed review of this 
literature see Kosorok & Laber 2019).65 Let 𝑋𝑋1 denote the participant ’s covariates at the time of the first 
randomization, and 𝑋𝑋2denote the interim data collected before the second randomization. 𝐴𝐴𝑡𝑡 denotes 
the assigned treatment at the 𝑡𝑡-th stage randomization, and 𝑌𝑌𝑡𝑡 the difference between the PEG 
measured after completing the 𝑡𝑡-th stage course of treatment and the participant’s baseline PEG score 
coded so that higher is better. Define 𝐻𝐻𝑡𝑡 as the participant history available at the t-th stage 
randomization, so that 𝐻𝐻1=(𝑋𝑋1) and 𝐻𝐻2=(𝑋𝑋1,𝐴𝐴1,𝑌𝑌1,𝑋𝑋2),𝑎𝑎𝑎𝑎𝑎𝑎  𝑯𝑯 =  (𝐻𝐻 1,𝐻𝐻2). A dynamic treatment 
regime (DTR) is a sequence of functions  𝒅𝒅=(𝑎𝑎1,𝑎𝑎2) that maps participants to treatments based on the 
available history. An optimal DTR maximizes the expectation of a prespecified cumulative outcome 𝑌𝑌=
𝑓𝑓(𝑌𝑌1,𝑌𝑌2). In our case the outcome of interest is the 24-week change from baseline in PEG so 𝑌𝑌 =𝑌𝑌2. The 
potential outcome under a regime 𝒅𝒅 is given by  
𝑌𝑌∗(𝐝𝐝)=� 𝑌𝑌∗(𝑎𝑎1,𝑎𝑎2)𝟏𝟏(𝑎𝑎1(𝐻𝐻1)=𝑎𝑎1)𝟏𝟏(d2(𝐻𝐻2)=𝑎𝑎2)
(𝑎𝑎1,𝑎𝑎2) 
where
 𝟏𝟏 is the indicator function that is equal to one when the condition is met and zero 
otherwise. The goal is to estimate 𝐝𝐝opt, the DTR that maximizes the value function 𝑉𝑉(𝐝𝐝)=
𝐸𝐸[𝑌𝑌∗(𝐝𝐝)]. The efficacy will be assessed in terms of the estimated value of the DTR 𝑉𝑉��𝐝𝐝̂�. The optimal 
DTR, 𝐝𝐝opt, is fundamentally unknowable in the same way that regression parameters are.  
 
Secondary objective 1: Estimate DTRs that optimally balance multiple outcomes, taking into account 
participant preferences for outcomes including pain intensity, pain interference, physical function, opi[INVESTIGATOR_2441], depression, anxiety, sleep duration and sleep disturbance.  
 A utility -based combination of multiple outcomes wil l be used Aim 2. These outcomes include level of 
pain, physical abilities, fatigue, anxiety, depressive symptoms, cognitive function, and overall enjoyment of life. Three combinations will be considered: 1) a combination of pain and physical abilities; 2) a combination of pain, physical abilities, and cognitive function; 3) a combination of all seven outcomes. 
By [CONTACT_580626], we can construct an optimal DTR that 
balances multiple competing outcomes and respects the relative importance of these outcomes to each participant (Butler et al). Future treatment decisions could be informed by [CONTACT_580627] v 7.0 47 9/1/2023  elicitation tool in combination with the estimated DTR to guide treatment decisions. Participant 
preferences will be elicited at baseline through a series of discrete choice tasks, and participant 
satisfaction with treatment will be measured after each stage of treatment to help calibrate the 
preference estimation. The efficacy will be assessed in terms of the estimated value, or expected 
patient-tailored combination of outcomes, of the DTR. 𝑉𝑉��𝐝𝐝̂�. 
 
Secondary objective 2: Estimate  DTRs that incorporate additional phenotypic markers (i.e., deep 
phenotypi[INVESTIGATOR_007]) collected on a sub -set of participants.  
 
Secondary objective 3: Assess whether  effectiveness is sustained  based on outcomes collected 24 
weeks after randomization to the second treatment.  
 The change in the PEG composite score collected 24 weeks after the start of the second treatment relative to  baseline will the efficacy endpoint for Secondary o bjective  3. This is identical to the primary 
efficacy endpoint except with a longer follow -up time. The efficacy will be assessed in terms of the 
estimated value of the DTR 
𝑉𝑉��𝐝𝐝̂�. 
 Exploratory objective s: Evaluate the (1) comparative effectiveness of individual treatments; (2) 
comparative effectiveness of different treatment regimes (i.e., a particular regime with a given set of 
rules at each decision point); and (3) impact of treatment order on outcomes.  
We can  test the null hypothesis that the value of two different DTRs are equal. Let 𝐝𝐝
[ADDRESS_763441] 
DTR that does not consider a participant’s phenotype (the best zero -order DTR). This DTR assigns every 
participant  the treatment with the best population  average treatment effect. Let 𝐝𝐝opt denote the 
optimal DTR that considers participant  phenotype. We can conduct two -sided tests of superiority of the 
hypothesis  
𝐻𝐻0:𝐕𝐕(𝐝𝐝0) =𝐕𝐕(𝐝𝐝opt)  
𝐻𝐻1:𝐕𝐕(𝐝𝐝0)≠ 𝐕𝐕 (𝐝𝐝opt)  
For the other interventions that are not the best, we can analogously define a DTR that always 
recommends each of these treatments and compare them to each other and to the optimal DTR.  
13.2.  SAMPLE SIZE  DETERMINATION  
 
Simulation Methodology Overview  
 
Simulatio n studies were used to determine the sample size for the trial using a grid search over 
potentially feasible sample sizes. The outcome measure was the difference in PEG at [ADDRESS_763442] in the simulation studies was how close the value of the 
estimated dynamic treatment regime, 𝑉𝑉�d𝑛𝑛��, was to the value of the optimal dynamic treatment 
regime 𝑉𝑉(dopt) for the difference. The percentage of optim al value is equal to 𝑉𝑉�d𝑛𝑛��/𝑉𝑉(dopt) (assuming  
𝑉𝑉�d𝑛𝑛�� is non-negative and 𝑉𝑉(dopt) is strictly positive ). Note that this is not a hypothesis test but a 
performance criterion that evaluates how close the estimated treatment regime is to the optimal 
treatment regime  
 The estimated value of the estimated dynamic treatment regime for each replicate was obtaine d using 
Monte -Carlo  methods and an independent out -of-sample data set. First, an out -of-sample data set was 
 
BEST Trial Protocol v 7.0 48 9/1/2023  generated using the same data generating distribution as the one used to generate the trial data for a 
given simulation scenario. A dynamic treatment regime is estimated on the replicate study data using Q-
learning.5,6  Then for every dynamic treatment regime, the estimated DTR is used to assign the out -of-
sample participants to  treatment sequences, and the estimated value of the DTR calculated (the 
expected outcome under each treatment is known for all out-of -sample participant s). Finally, the ratio 
of the value from estimated DTR to the optimal DTR is calculated.  
 
The ana
log to power in this setting is the probability that the ratio of the value from a DTR estimated on 
a trial with sample size 𝑎𝑎 rel
ative to the value of the optimal DTR is greater than or equal to a fixed 
performance cutoff δ . 
𝑃𝑃�𝑉𝑉� d𝑛𝑛��÷𝑉𝑉(dopt)≥ 𝛿𝛿�  
We ch
ose a performance cut-off δ of 0.9, so that for a simulated trial to be considered a success the 
value of the DTR estimated on that simulation replicate’s data must be within 90% of the optimal DTR’s value. 
 There is no analog to Type -I error for this  because a null scenario would imply that all treatments are 
equally ineffective and no biomarkers matter, and in this situation any dynamic treatment regime is trivially optimal.  
 Simulations were conducted using R version 4.0.[ADDRESS_763443], 𝑌𝑌,  is the difference in PEG at 24 
weeks relative to baseline 𝑌𝑌=𝑌𝑌2,.  
Let 𝐴𝐴𝑡𝑡,𝑘𝑘 denote the indicator function 𝟏𝟏(Intervention  𝑘𝑘 given for stage 𝑡𝑡) that is one whenever 
intervention  𝑘𝑘 is given for stage 𝑡𝑡  and zero otherwise. For the outcome after each stage, 𝑌𝑌 𝑡𝑡 , denote 
the conditional expectation of 𝑌𝑌𝑡𝑡  given the history and intervention by  𝑄𝑄𝑡𝑡(𝐻𝐻𝑡𝑡,𝐴𝐴𝑡𝑡)=𝐸𝐸[𝑌𝑌𝑡𝑡|𝐻𝐻𝑡𝑡,𝐴𝐴𝑡𝑡]. Then 
the data generating model for one of the simulation scenarios with a single covariate associated with 
the outcome is:  
𝑄𝑄1(𝐻𝐻1,𝐴𝐴1)= .1𝐴𝐴1,0+ .25𝐴𝐴1,1+ .3𝐴𝐴1,2+ .4𝐴𝐴1,3+ .3𝑋𝑋1𝐴𝐴1,3+ .25𝑋𝑋2−.25𝑋𝑋3  
𝑄𝑄2(𝐻𝐻2,𝐴𝐴2)= .1𝐴𝐴2,0+ .25𝐴𝐴2,1+ .3𝐴𝐴2,2+ .4𝐴𝐴2,3+ .3𝑋𝑋1𝐴𝐴2,3−.1𝐴𝐴2,1𝐴𝐴2,2 − 1𝐴𝐴2,1𝐴𝐴2,3
− .1𝐴𝐴2,2𝐴𝐴2,3        + . 25𝑋𝑋2−.25𝑋𝑋3 
𝑌𝑌1=𝑄𝑄1(𝐻𝐻1,𝐴𝐴1)+ϵ1,      ϵ1∼ 𝑁𝑁 (0,1) 
𝑌𝑌2=𝑄𝑄2(𝐻𝐻2,𝐴𝐴2)+ϵ2, ϵ2∼ 𝑁𝑁 (0,1) 
𝑌𝑌=𝑌𝑌2 
Recall that in the first stage exactly one intervention can be given, while in the second stage one or two int
erventions may be given.  
The covariates were generated independently with 𝑋𝑋1∼Bern( . 5), 𝑋𝑋𝑙𝑙∼Bern(𝑝𝑝𝑙𝑙), l = 2, ..., 5  where and 
𝑝𝑝𝑙𝑙 ranges from 0.5 to 0.9 and 𝑋𝑋𝑙𝑙 are coded to take values { −1, 1} instead of  {0, 1}  and an additional five 
normally distributed covariates 𝑁𝑁(0, .5) .  There were a total of ten covariates, one of which was 
 
BEST Trial Protocol v 7.0 49 9/1/2023  associated with the  outcome through a treatment interaction, and two prognostic covariates that 
influence the outcome but was not associated with response to treatment. The  𝑄𝑄-functions were 
estimated using mis -specified models that included interaction terms for every treatment by [CONTACT_580628], and the models were fit by [CONTACT_580629].  
These settings give rise to the following optimal rule:  
𝑋𝑋1 𝐴𝐴1opt 𝐴𝐴2opt Response to treatment at 24 weeks 
compared to baseline  
𝑋𝑋1 =−1 Any intervention  𝐴𝐴2,1 and 𝐴𝐴2,2 in 
combination  0.45 
𝑋𝑋1= 1 Any intervention  𝐴𝐴2,2 and 𝐴𝐴2,3 in 
combination  0.9 
 
The optimal rule above, 𝐝𝐝opt, has an average (over the values of X 1) response of (0.45+0.9) = 0.675. An 
example  DTR with a value that is within 90% of the optimal value is:  
𝑋𝑋1 𝐴𝐴1opt 𝐴𝐴2opt Response to treatment at 24 weeks 
compared to baseline  
𝑋𝑋1 =−1 Any intervention  𝐴𝐴2,1 and 𝐴𝐴2,2 in 
combination  0.45  
𝑋𝑋1= 1 Any intervention  𝐴𝐴2,1 and 𝐴𝐴2,3 in 
combination  0.85  
Whic h assigns 𝐴𝐴2,1instead of 𝐴𝐴2,2  as part of the combination for biomarker positive patients in stage 
two.  The average response (over the values of biomarker X 1) is 0.65.  
 
The table below shows 𝐝𝐝optand other treatment rules for comparison.  
 
Treatment Regime  Average response to treatment 
at 24 weeks compared to 
baseline  
𝐝𝐝opt (incorporates phenotypic markers)  0.[ADDRESS_763444] stage and  𝐴𝐴2,2 and 𝐴𝐴2,3 in combination in the second 
stage (no phenotypic markers)  0.[ADDRESS_763445] 90% of the optimal value for this scenario is 81% 
based on 5,000 replicates (Monte Carlo  standard error ≈ 0.009 )  
The treatment effect sizes were based on systematic review by [CONTACT_522145]18,59 and an internal review conducted by [CONTACT_580630]’s Interventions Working Group. 
The standardized treatment effect sizes were assumed to be 0.[ADDRESS_763446] Trial Protocol v 7.0 50 9/1/2023  Simulation Results  
A total of 6 30 complete cases yields 80% probability to attain a value within at least 90% of the optimal 
value. Assuming ~15% of participants fail to complete the study through the primary efficacy endpoint, a 
total sample size of  approximately  [ADDRESS_763447] 90% of the 
possible reduction in PEG 80% of the time. The 15% drop -out is intended as an upper -bound, not the 
actual anticipated drop -out, and is based on a threshold provided by [CONTACT_580631] -out. 
 
13.3.  POPULATIONS FOR A NALYSES  
 All participants  
The “All participants” population will consist of all participants consented to the study.  
 
All Randomized Population  
The All Randomized population will consist of all participants randomized and statistical analyses will 
follow the intention to treat approach  as much as possible. The All Randomized population will be used 
in primary, secondary, and exploratory analyses.  
 
13.4.  STATISTICAL ANALYSES  
 
13.4.1.  GENERAL APPROACH  
Below we provide an overview of the general statistical approach planned for this trial. A complete and detailed statistical analysis plan (SAP) will be completed prior to any evaluation of primary or secondary outcome data stratified by [CONTACT_580632] . 
The primary goal will be to estimate a two -stage dynamic treatment regime that maximizes the 
expected reduction in PEG between the beginning and the end of the study. We will use Q -learning for 
this approach .[ADDRESS_763448] will be to estimate a two -stage DTR that minimizes 
some combination of multiple outcomes, where the ideal trade-off is estimated using participant 
preferences. Here we will use a latent variable approach: We will assume that that the op timal 
combination, or preferred trade-off, of outcomes for  each  individual can be represented as a simple 
convex combination of outcomes, where the participant-specific weights of  the convex combination are 
unobserved and depend on the participant’s covariates and responses to questionnaires. To estimate 
and make inferences on these weights, we will estimate the posterior distribution of these 
latent  weights conditional on the covariates and questionnaire responses. This is what was proposed, 
for example, i n Butler [ADDRESS_763449] Trial Protocol v 7.0 51 9/1/[ADDRESS_763450] with research staff and regular patient engagement efforts. Finally, protocols for discontinuation of study treatment that are not tolerated are planned to enhance retention. We will continue to follow  all participants until the end of the study and will utilize 
alternative forms of data collection for those who do not attend planned study visits (e.g., telephone administration or online data collection). Despi[INVESTIGATOR_120502], missing data will arise a nd, as needed 
and appropriate, will be addressed using non -parametric multiple imputation procedures. Sensitivity 
analyses will be presented in detail as part of the SAP. 
13.4.2.  ANALYSIS OF THE PRIM ARY EFFICACY ENDPOIN T(S)  
Complete details will be  provided in the formal Statistical Analysis Plan for the study.  
 
13.4.3.  ANALYSIS OF THE SECO NDARY ENDPOINT(S)  
Complete details will be provided in the formal Statistical Analysis Plan for the study.  
 
13.4.4.  SAFETY ANALYSES  
No safety analyses are planned  other than descriptive summaries and data listings of reported adverse 
events.  
13.4.5.  BASELINE DESCRIPTIVE  STATISTICS  
Complete details will be provided in the formal Statistical Analysis Plan for the study.  
 
13.4.6.  PLANNED INTERIM ANAL YSES  
 
No interim analyses are planned for the study.  Adaptation to the design,  i.e. the second stage 
randomization probabilities , is planned  and details will be included in a future Statistical Analysis Plan.  
Briefly, overall proportions of participants assigned to augment or switch will be monitored. If 
proportions deviate meaningfully from assumptions, we will consider shifting randomization probabilities within Group 3 ( e.g., from 50/50 to 60/40 augment/swi tch).  
 
13.4.7.  SUB -GROUP ANALYSES  
N/A 
 
13.4.8.  TABULATION OF INDIVIDUAL PARTICIPANT DATA 
Complete details will be provided in the formal Statistical Analysis Plan for the study.  
 
13.4.9.  EXPLORATORY ANALYSES  
Complete details will be provided in the formal Statistical Analysis Plan for the study.  
 
BEST Trial Protocol v 7.0 52 9/1/[ADDRESS_763451] appropriate treatment(s) based on their individual characteristics, lifestyle, and environment and optimize their outcomes , how participation in the 
protocol will allow participants to receive treatment(s) that have been independently shown to clinically improve pain intensity and interference and may improve other outcomes such as function , why their 
participation is important, and how their data will contribute to the research. The goal is to obtain buy -
in from potential participants on the study expectations and requirements  as a whole and explain clearly 
what they can expect from participation in the study (e.g., expected study duration given their enrollment date, possibilities of participating in two different treatment s or remaining in one treatment 
assignment  throughout the study, etc.).  The master consent form provides  details about the possible 
treatment(s) each potential participant may receive.  
The master consent document describes the intervention process and procedures invo lved in the BEST 
trial. Participants will be informed that their consent will allow them to be assigned to a t reatment , 
which may be augmented or changed during the intervention period. If they are not willing to provide consent, they are not eligible for the study.   
Note that participants will also be asked to consent to storage of and future use of their  data and  
biospecimens separately from their consent to study participation.  Participants will be able to consent 
to the study (including use of biospecimens in BEST ) but opt out of having their data and biospecimens 
stored for future use.  Participants will also have th e option to be considered for participation in more 
comprehensive phenotypi[INVESTIGATOR_4585], which include brain MRI, quantitative sensory testing, and an 
advanced spi[INVESTIGATOR_25342].   
Each consented participant will  receive a signed copy of the study consent. The si te's signed consent 
form copy is to be filed with other confidential participant information. Upo n completion of the 
consenting process, each participant’s informed consent information is  entered into the data 
management system for study tracking purposes.  During the study, consent information is updated in 
the data management system when the pa rticipant  notifies the study that they would like to modify 
their consent  or withdraw from the study.  After study completion, participants may not be able to 
modify  their consent for biospecimen use because all remaining biospecimens will be transferred  the 
NIH biospecimen repository  which will control access to the biospecimens . 
This study will be reviewed under a single institutional review board (IRB) at Advarra®.  All sites will rely 
on the Advarra® IRB, and a reliance agreement, either an IRB Authorization Agreement (IAA) or SMART 
IRB agreement, will be established for each site institution.  If an institution has a master service agreement established with Advar ra®, a study -specific IAA will not need to be established.  Once fully 
executed, a copy of the IAA, SMART IRB agreement, will be submitted to the DAC, with the original 
agreement filed on site. If the institution is under a master service agreement with Advarra®, the site 
will need to supply a copy to the DAC.  The DAC will ensure that every consent form meets federal 
 
BEST Trial Protocol v 7.0 53 9/1/[ADDRESS_763452]  study investigators and study teams will comply 
with applicable regulatory requirements, namely, ICH, GCP and other regulatory requirements including Title 45 Part 46 of the Code of Federal Regulations (45 CFR 46), 21 CFR 11 (Electronic Records), 21 CFR 
50 (Protection of Human Subjects), 21 CFR 54 (Financial Disclosure of Clinical Investigators), 21 CFR 56 (Institutional Review Boards), and 21 CFR 312 (Invest igational New Drug Application).  
14.1.2.  CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO 
PARTICIPANTS 
Consent forms describing in detail the study intervention, study procedures, and risks are given to the 
participant and written documentation of informed consent is required prior to starting administration 
of the study intervention.  The following consent materials are submitted with this protocol:  
• Adult Consent Form_English  
Basic consent elements and appropriate additional elements as outlined in 45  CFR §46.116 and 21 CFR 
§50.25 include:  
• Statement that the study involves research;  
• Explanation of the purposes of the research, the expected duration of the subject’s participation, and a description of the procedures to be followed;  
• A statement of the co nditions and period of time under which the participant’s data will be 
stored and will be accessible; 
• A description of any foreseeable risks or discomforts to the participant;  
• Reasonably expected benefits to participant  or others;  
• Disclosure of alternative  procedures;  
• Confidentiality measures;  
• Explanation of compensation and medical treatment, if any, for injury;  
• A statement that participation is voluntary, refusal to participate will involve no penalty or loss of benefits and that the participant may discontinue participation in any time without penalty or 
loss of benefits; and  
• An explanation of whom to contact [CONTACT_580633] ’s rights, and whom to contact [CONTACT_44751] a research -related injury to 
the participant, for research questions, or for questions about rights.  
Additional elements include:  
• Unforeseeable risks to the participant  and/or to the fetus or embryo in case of pregnancy;  
• Circumstances under which participation may be terminated without regard to participant’s 
consent;  
• Additional costs to participant resulting from study participation;  
• Consequences of the decision to with draw and procedures for orderly termination of 
participation by [CONTACT_2299]; 
• New study findings which may affect the participant’s decision to continue; and 
• Approximate number of study participant s. 
Informed consent form requirement for clinical trials : 
 
BEST Trial Protocol v 7.0 54 9/1/[ADDRESS_763453] 
wording to be included in the documents reads : “A description of this clinical trial will be available on 
http://www.ClinicalTrials.gov , as required by U.S. Law. This Web site will not include information that 
can identify you. At most, the Web site will include a summary of the results. You can search this Web 
site at any time.”  
 
14.1.3.  CONSENT PROCEDURES AND DOCUMENTATION 
Informed consent is a process that is initiated prior to the individual agreeing to participate in the study 
and continues throughout the individual’s study participation. Consent forms will be IRB -approved,  and 
the participant will be asked to read and review the document. The investigator or study coordinator 
will explain the research study to the participant and answer any questions that may arise. A verbal explanation will be provided in terms suited to the participant’s comprehension of the purposes, procedures, and potential risks of the study and of their rights as research participants.  Participants will have the opportunity to caref ully review the written consent form and ask questions prior to signing. 
The participants should have the opportunity to discuss the study with their family or surrogates or think about it prior to agreeing to participate. The participant will sign the informed consent document prior to any procedures being done specifically for the study. Participants must be informed that participation is voluntary and that they may withdraw from the study at any time, without prejudice. A copy of the informed consent document will be given to the participants for their records. The informed consent 
process will be conducted and documented in the source document (including the date), and the form 
signed, before the participant undergoes any study -specific procedures. In ca ses where a participant is 
required to be re -consented, re-c onsent may also be obtained remotely  with prior permission from the 
DAC . In this case, the consent form will be provided to the participant. It will be reviewed with the 
participant over the phone or during a video call. The participant may sign the consent form and return 
it to the site, or the form may be signed electronically, provided a software tool that is compliant with the Code of Federal Regulations (CFR) 21 Part 11 concerning electronic signatures is available at the site. The rights and welfare of the participants will be protected by [CONTACT_34693].  
14.1.4.  STUDY DISCONTINUATION AND CLOSURE 
The trial may be temporarily suspended or prematurely terminated if there is sufficient reasonable 
cause (see examples below). Written notification, documenting the reason for study suspension or termination, will be provided by [CONTACT_21224], investigators, the NIAMS , the Food and Drug Administration and other relevant regulatory authorities. If the study is 
prematurely terminated or suspended, the Principal Investigator [INVESTIGATOR_580557], the IRB, and the sponsor and will provide the reason(s) for the termination or 
suspension. Study participants will be contact[INVESTIGATOR_530], as applicable, and be informed of changes to study visit schedule.  Please refer to Section 11, Study Intervention Discontinuation and Participant 
Discontinuation/Withdrawal,  for handling of enrolled study participants.  
Circumstances that may warrant termination or suspension of the study include, but are not limited to:  
• Determination of un expected, significant, or unacceptable risk to participants  
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable  
 
BEST Trial Protocol v 7.0 55 9/1/2023  The study may resume once concerns about safety, protocol compliance, and data quality are  
addressed, and satisfy NIAMS, the IRB and/or other regulatory agencies.  
14.1.5.  CONFIDENTIALITY AND PRIVACY  
Participant confidentiality and privacy is strictly held in trust by [CONTACT_3486], their 
staff, and the sponsor(s). This confidentiality is extended to cover testing of biological samples and genetic tests in addition to the clinical information relating to participants. Therefore, the study documentation, data, and all other information generated will be held in strict confidence.  
All research activities will be conducted in as private a setting as possible.  
The study monitor, other authorized representatives of the sponsor, representatives of the IRB, or 
regulatory agencies may inspect all documents and records required to be maintained by [CONTACT_1275], including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study. The clinical study site will permit access to such records. 
The study participant’s contact [CONTACT_580634]. At the end of the study, all records will continue to be kept in a secure location for as 
long a period as dictated by [CONTACT_3488], Institutional policies, or sponsor requirements. 
Study participant research data  used for purposes of statistical analysis and scientific reporting will be 
securely transmitted to and stored at the DAC . The study data entry and study management systems 
used by [CONTACT_580635] C will be secured and password protected  (see Sections 5.2.3 . and 
14.1.11. ). At the end of the study, data  will be de-identified and sen t to an NIH data repository.  
Certificate of Confidentiality  
To further protect the privacy of study participants, a Certificate of Confidentiality (COC) has been 
automatically issued by [CONTACT_7681] (NIH).  This certificate protects identifiable 
research information from forced disclosure. It allows the investigator and others who have access to 
researc h records to refuse to disclose identifying information on research participation in any civil, 
criminal, administrative, legislative, or other proceeding, whether at the federal, state, or local level. By [CONTACT_305219], Certificates of Confidentiality help achieve the research objectives and promote participation in studies by [CONTACT_4205][INVESTIGATOR_21783].  
 
14.1.6.  FUTURE USE OF STORED SPECIM ENS AND DATA  
 
BEST  will be collecting specimens on all participants. Strict confidentially standards are in place and will 
be maintained to protect the privacy of study  participants. Biospecimen samples will be labeled with a 
unique identifier that does not contain any protected health information or otherwise identify a 
participant. Biospecimens collected will not be stored long-term at the clinical sites but rather will be deposited in batches at the NYU Langone Health Center for Biospecimen Research and Development 
(CBRD) .  These specimens will not be individually identifiable by [CONTACT_25437], clinical centers, or DAC 
personnel. The DAC will develop and maintain a tracking system whereby [CONTACT_580636] o f consent for their use of any stored samples for future studies. Participants can ask that any 
specimens still in storage be destroyed and not included in future analyses.  
 
BEST Trial Protocol v 7.0 56 9/1/2023  Genetic studies utilizing the participant’s DNA will be conducted in  BEST . Other “ omics” studies will also 
be conducted in  BEST .  These may include studies to evaluate the RNA transcriptome and the 
microbiome, and they could potentially include studies involving the metabolome, the epi[INVESTIGATOR_307999], and 
the proteome.  Data collected for this study will be analyzed and stored in the secure servers at the DAC and submitted to the secure cloud -based data portal at the DAC per the schedule defined in the BACPAC 
Data Transfer SOP.  After the study is completed, the de-identified data will be transmi tted to and 
stored at a n NIH-approved  repository for use by [CONTACT_21227]. 
Permission to transmit data to the NIH repository  will be included in the informed consent.  
With the participant’s approval and as approved  by [CONTACT_1758]’s single IRB, de-identified biological 
samples will also be stored at a NIH’s HEAL repository after the study is completed. These samples could be used for future research.  
During the conduct of the study, an individual participant can choose to withdraw consent to have biological specimens stored for future research. However, withdrawal of consent with regard to 
biosample storage may not be possible after the study is completed. When the study is completed, 
access to study data and/or samples will be provided through the NIH data and biospecimen repositories. 
14.1.7.  KEY ROLES AND STUDY GOVERNANCE  
 
The BEST  Executive Leadership Committee (ELC) will  provide leadership for the implementation of the 
BEST trial and will serve as the primary decision-making body regarding actions taken in response to 
challenges that arise implementing the study protocol.  Membership will include the BEST Protocol Co -
Chairs, the BEST Project Manager, the NIAMS BACPAC Program Coordinator, and two BEST site PIs (serving on a rotating basis).  Primary duties of the ELC will include interact ing with NIH regarding the 
progress of the trial  towards  key milestones , facilitat ing the BEST Operations Committee (OC) meetings, 
and provid ing high-level reporting on the trial  to the BACPAC Steering Committee at regular intervals . 
The ELC will also be responsible for determining  whether protocol modifications are needed and for 
seek ing input/approval from the BACPAC Steering Committee  as needed.  
The BEST OC  will provide feedback to the ELC regarding the conduct of the study. OC bi -weekly meetings 
will provide a forum for s ite PIs to share implementation successes and challenges with the broader set 
of OC members to foster re finement of best practices regarding conduct of the study .  Membership will 
include ELC members, BEST site PIs, NIH/NIAMS representatives, and BEST intervention experts, as well as experts from the BACPAC Adaptive Design Expert Group , Intervention Working Group , Deep 
Phenotypi[INVESTIGATOR_580558] , and Theoretical Model Working Group. 
 
14.1.8.  SAFETY OVERSIGHT  
NIAMS will establish an independent D ata and Safety Monitoring Board (DSMB) charged with  oversight 
of data quality, study integr ity, and safety of participants.  Per NIAMS requirements, all SAEs regardless 
of the expectedness and relatedness must be reported to the NIAMS and the DSMB through the NIAMS Executive Secretary within [ADDRESS_763454] Trial Protocol v 7.0 57 9/1/2023  participants are not exposed to undue risks.  The DAC will submit a summary report of 
recommenda tions  after each DSMB meeting to the  central IRB .  After IRB review, the summary of 
recommendations will be distributed to the site investigators to store with study documentation.  
The DSMB will make recommendations as to whether an  intervention or the entire study should be 
stopped for safety reasons based on periodic monitoring of adverse events and other safety parameters.  
Regularly scheduled DSMB meetings will be held to review safety data reports prepared by [CONTACT_580637], laboratory parameters, and other 
safety outcomes.  Ad hoc DSMB  meetings to review safety data can also occur if triggered by [CONTACT_580638].  
Once a determination is made to recommend discontinuation of the  study or a specific intervention for 
safety  reason s, the DSMB’s deliberations and rationale for arriv ing at the recommendation will be 
shared with the PI [INVESTIGATOR_485483]. T he DAC will prepare a report for the NIAMS Project Office r and 
the Operations  Committee that summarizes the results of analyses supporting the recommendations, 
the stoppi[INVESTIGATOR_580559], and the DSMB’s summary of their deliberations to arrive at the 
decision.  The DAC  will then work with the Operations Committ ee to  develop an appropriate 
communication plan for the various stakeholders.   
DSMB Members  
Members of the DSMB  are independent experts chosen by [CONTACT_580639]. They are not associated with the trial or with th e pharmaceutical companies that supply 
the study agents. Committee members’ areas of expertise span the disciplines relevant to the conduct 
of this clinical trial, including clinical trials, pharmacology, biostatistics, and clinical care of participants 
with cLBP . 
DSMB Mandates  
The DSMB  has the responsibility to review the research protocol and other study materials and to 
evaluate the progress of the trial overall and at each participating clinical center. This includes accrual, data quality and completeness, epi[INVESTIGATOR_580560], hospi[INVESTIGATOR_602] , mortality, other toxicities, 
and protocol violations. NIAMS expects expedited reporting of SAEs, Unanticipated Problems, and 
Protocol deviations that impact participant safety to occur within [ADDRESS_763455] Trial Protocol v 7.0 58 9/1/[ADDRESS_763456] principal investigators, the DAC statistician s (blinded and unblinded) , NIAMS representatives , 
and, on occasion , other key personnel will participate in the meetin gs’ open sessions.  Open sessions will 
include but not be limited to  consideration of recruitment, retention, and general scientific issues. The 
DSMB ’s voting members will discuss the unblinded by -treatment data  for each intervention in a closed 
session.  Th ese data include but are not limited to adverse events, and material that should be kept 
confidential from the investigators.  
Frequency and content of reports to the DSMB  
In advance of each meeting, the unblinded statistician at the DAC  will prepare a report for DSMB review. 
The report will contain the following categories of information aggregated by [CONTACT_1570] , where 
applicable, as well as any additional information required by [CONTACT_4318] : 
• Current enrollment status and timeline for completion of foll ow-up 
• Adverse events reported, both serious and non -serious, including hospi[INVESTIGATOR_580561]  
• Major and minor protocol violations and deviations  
• Numbers of participants whose study medication is discontinued  
Decisions on the labeling of treatment groups i n the safety reports  and other considerations to lessen 
the chance of accidental unmasking will be determined at the first meeting of the DSMB.   The unblinded 
DAC statistician will provide the treatment for each code to DSMB members as needed, a nd the same 
code mappi[INVESTIGATOR_580562].  
Serious events are reported to the NIAMS within 48 hours of the investigator becoming aware of the 
event.  
Frequency, content, and distribution of meeting reports  
Following each meeting of the DSMB,  the meeting recommendations and open meeting minutes are 
drafted by [CONTACT_580640],  but are not limited to , questions raised by [CONTACT_40746],  monitoring recommendations, and recommendations for the continuation of treatments  or the 
study as a whole.  These minutes are reviewed and approved by [CONTACT_580641] .  The NIAMS 
executive secretary will prepare a summary o f the questions raised by [CONTACT_580642], monitoring 
recommendations, and recommendations for the continuation of treatments. The meeting 
recommendations and minutes  will be distributed confidentially to meeting participants. The NIAMS 
executive secretary also prepares a closed session minutes (if applicable) for distribution to BEST 
investigators and their IRBs.  
14.1.9.  CLINICAL MONITORING  
Clinical site monitoring is conducted to ensure that the rights and well-being of study  participants are 
protected, that the reported study  data are accurate, complete, and verifiable, and that the conduct of 
the study  is in compliance with the currently approved protocol/amendment(s), with International 
 
BEST Trial Protocol v 7.0 59 9/1/2023  Conference on Harmonisation Good Clinical Practice (ICH GCP), and with applicable regulatory 
requirement(s).   Monitoring for this study will be performed by [CONTACT_580605] . 
Areas of Focus  
• Staff training  
• Human subjects protection  
• Protocol compliance  
• Regulatory compliance  
• Laboratory SOPs and compliance  
• Quality assurance  (QA)  
• Safety 
• Adverse event reporting  
• Integrity of research data and samples  
Two types of data monitoring will be conducted during the study: on -site monitoring and central 
monitoring.  On-site monitoring refers to a review of the data that takes place at the clinical site whereas central monitoring refers to activities that can be conducted at the data coordinatin g center.  
Monitoring Activities will include:  
• Review of credentials, training records, and delegation of duties logs  
• Review of 100% of Consent Forms  
• Review of reports on missed events, missing data, protocol deviations, and unanticipated problems  
• Comparison of CRFs to source documentation to ensure data are accurate and complete  
• Review of documentation for AEs, SAEs, and UPs  
• Review of critical fields such as eligibility, study endpoints, and SAEs  
• Regulatory Files: Limited reviews at interim visits , e.g., IRB annual reviews, safety reporting, IRB 
submissions of protocol deviations, and updated essential documents  
• Laboratory Review: Full laboratory review of processing and storage of specimens at first and close -out visits and at least biannually.  Assessment of laboratory specimens stored at the 
clinical site  
 
The DAC will provide copi[INVESTIGATOR_580563] -site monitoring reports within [ADDRESS_763457]  Clinical Monitoring Plan (CMP). The 
CMP will describe in detail who will conduct the monitoring, at what frequency monitoring will be done, 
at what level of detail monitoring will be performed, and the distribution of monitoring reports.   
 
14.1.10.  QUALITY ASSURAN CE AND QUALITY CONTR OL 
Each clinical site will perform internal quality management of study conduct, data and biological 
specimen collection, documentation and completion.  An individualized quality management plan will be developed to describe a site’s quality management.  
Quality control (QC) procedures will be implemented beginning with the data entry system. The database will include real-time data QC checks .  Any missing data or data anomalies will be 
communicated to the site(s) for clarification/resolu tion.  
 
BEST Trial Protocol v 7.0 60 9/1/2023  Following written SOPs, the monitors will verify that the clinical trial is conducted, data are generated , 
and biological specimens are collected, documented (recorded), and reported in compliance with the 
protocol, International Conference on Harmonization Good Clinical Practice (ICH GCP), and applicable 
regulatory requirements (e.g., Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP)).  
The investigational site will provide direct access to all trial related sites, source data/docum ents, and 
reports for the purpose of monitoring and auditing by [CONTACT_580605], and inspection by [CONTACT_90471]. 
Magnetic Resonance Imaging (MRI) Quality Control of Brain Images 
Even when comparable hardware and experimental procedures are employed in brain imaging studies with functional magnetic brain imaging (fMRI) and structural MRI, between -site variability may arise.  
This may come from a number of sources including: small f laws in data collection equipment/software, 
subtle differences in experimenters’ administration of standardized protocols, and differences between 
scanner brands.  It is not possible to quantify these variables using non -human models (e.g., brain MRI 
phant oms).  To control for these variables, the same member of the BEST Trial MRI domain expert’s 
research team will travel to each trial site.  This study member will undergo MRI scan protocols that are 
identical to the phantom scans.  These scans include: structural T1 brain image, resting state brain 
image, and diffusion tensor structural brain image.  Performing these scans on the same human at each 
trial site will allow researchers to identify, measure, and minimize inter -site variability among MRI 
scanners .  Data from these scans will not be included in the BEST Trial dataset.  
 
14.1.11.  DATA HANDLING AND RECORD KEEPI[INVESTIGATOR_580564], which is for purposes of statistical analysis and scientific reporting, will 
be transmitted to and stored at the DAC. The study data entry and study management systems used by [CONTACT_580643]. At the end of the study, all study databases will be de -identified and archived at an  NIH-approved data repository.  
Risk of d isclosure will be minimized through the use of several procedures.  The D AC operates under 
FISMA (Federal Information Security Management Act) guidelines, and the data management system 
used in BEST  is compliant with FDA [ADDRESS_763458] Trial Protocol v 7.0 61 9/1/2023  Data recorded in the electronic case report form (eCRF) derived from source documents should be 
consistent with the data recorded on the source documents.  
Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MEDDRA) and 
concomitant medications will be coded using the National Drug Code (NDC) Directory.  
Clinical data (including adverse events (AEs), concomitant medications, and expected adverse reactions data) and clinical laboratory data will be entered into CDART , a [ADDRESS_763459] protection and internal quality checks, 
such as automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate. Clinical data will be entered dire ctly from the source documents.  
14.1.13.  STUDY RECORDS RETENT ION  
Study documen ts should be retained for a minimum of 3 years after the completion of research in 
accordance with HHS regulations.   These documents will be retained for a longer period, however, if required by [CONTACT_427]. No records will be destroyed without the written consent of NIAMS. It is the responsibility of the study sponsor to inform the investigators when these documents no longer 
need to be retained.  
14.1.14.  PROTOCOL DEVIATIONS  
A protocol deviation is any noncompliance with the study protocol, International Co nference on 
Harmonization Good Clinical Practice (ICH GCP), or Manual of Procedures (MOP) requirements. The noncompliance may be either on the part of the participant, the investigator, or the study site staff.  As a result of deviations, corrective action s are to be developed by [CONTACT_3483].   
These practices are consistent with ICH GCP:  
• 4.5 Compliance with Protocol, Sections 4.5.1, 4.5.2, and 4.5.3  
• 5.1 Quality Assurance and Quality Control, Section 5.1.1  
• 5.20 Noncompliance, Section s 5.20.1, and 5.20.2.  
Protocol deviations require reporting to the DAC, and to the oversight IRB, and additional 
source/supporting documents may be requested and should be kept in the participant’s record.  Sites 
should notify the DAC in accordance with the Manual of Procedures.   
It is the responsibility of the site investigator to use continuous vigilance to identify and report deviations within [ADDRESS_763460] be sent to the reviewing IRB per their policies , as 
applicable. The site investigator is responsible for knowing and adhering to the reviewing IRB requirements. Further details about the handling of protocol deviations will be included in the MOP.  
 
14.1.15.  PUBLICATION AND DATA  SHARING POLICY  
This study will be conducted in accordance with the  BACPAC DAC Data Portal Protocol, Data Transfer 
SOP, BACPAC Data Access and Publications Policy , and the following publication and data sharing 
policies and regulations:  
 
BEST Trial Protocol v 7.0 62 9/1/2023  National Institutes of Health (NIH) Public Access Policy, which ensures that the public has access to the 
published results of NIH -funded  research. It requires scientists to submit final peer -reviewed journal 
manuscripts that arise from NIH funds to the digital archive PubMed Central  upon acceptance for 
publication.  
This study will comply with the NIH Data Sharing Policy and Policy on the D issemination of NIH -Funded 
Clinical Trial Information and the Clinical Trials Registration and Results Information Submission rule. As such, this study  will be registered at ClinicalTrials.gov, and results information from this trial will be 
submitted to ClinicalTrials.gov. In addition, every attempt will be made to publish results in peer -
reviewed journals.  Data from this study may be r equested from other researchers at the 
discontinuation of BACPAC by [CONTACT_580644]-approved  HEAL repository.    
In addition, this study will comply with the NIH Genomic Data Sharing Policy, which applies to all NIH-
funded research that generates large-scale human or non -human genomic data, as well as the use of 
these data for subsequent research. Large-scale data inclu de genome-wide association studies (GWAS), 
SNP arrays, and genome sequence, transcriptomic, epi[INVESTIGATOR_141214], and gene expression data.  
The BACPAC Data Access and Publication s Committee will be responsible for developi[INVESTIGATOR_580565].   
14.1.16.  CONFLICT OF INTEREST POLICY  
The independence of the BEST  study from any actual or perceived influence, such as by [CONTACT_81477], is critical.  Therefore, any actual conflict of interest of investigators who have a role in the  design, conduct, analysis, publication, or any aspect of this study will be disclosed and 
managed. Furthermore, investigators who have a perceived conflict of interest will be required to have such conflicts managed in a way that is appropriate to their participation in the design and conduct of 
this trial.  The study leadership in conjunction with the NIAMS has established policies and procedures 
for investigators to disclose all conflicts of interest and has established a mechanism for the management of all reported dualities of interest.  
  
 
BEST Trial Protocol v 7.0 63 9/1/[ADDRESS_763461] Trial Protocol v 7.0 64 9/1/[ADDRESS_763462] Trial Protocol v 7.0 65 9/1/2023  15. REFERENCES  
1. Deyo RA, Dworkin SF, Amtmann D, Andersson G, Borenstein D, Carragee E et al. Report of the NIH 
Task Force on research standards for chronic low back pain. Phys Ther. 2015;95(2):e1-
e18.DOI:10.2522/ptj.2015.95.2.e1.  
2. RFA-AR-19-027: Heal INITIATIVE: Back PAIN Consortium (bacpac) research program data Integration, 
algorithm development and operations Management Center (u24 clinical trial not allowed). National Institutes of  Health. Retrieved from: https://grants.nih.gov/grants/guide/rfa -files/rfa-ar -19-
027.html.  
3. Katz JN. Lumbar disc disorders and low -back pain: socioeconomic factors and consequences. J Bone 
Joint Surg Am. 2006;[ADDRESS_763463] 2:21-24. DOI:10.2106/JBJS.E.[ZIP_CODE].  
4. Theis KA, Roblin DW, Helmick CG, Luo R. Prevalence and causes of work disability among working-age U.S. adults, 2011 -2013, NHIS. Disabil Health J. 2018;11(1):108- 115. 
DOI:10.1016/j.dhjo.2017.04.010.  
5. Schulte PJ, Tsiatis AA, Laber EB, Davidian M. Q - and A -learning Methods for Estimating Optimal 
Dynamic Treatment Regimes. Stat Sci. 2014;29(4):640 -661. DOI:10.1214/13-STS450.  
6. Watkins C.J, Dayan, P. Technical Note: Q -Learning. Machine Learning. 1992; 8, 279–292. 
https://doi.org/10.1023/A:1022676722315 
7. Baumeister H, Reichler L, Munzinger M, & Lin J. The impact of guidance on Internet -based mental 
health interventions — A systematic review. Internet Interventions. 2014; 1(4), 205-215. 
doi:10.1016/j.invent.2014.08.003 
8. Crits -Christoph P. Training in empi[INVESTIGATOR_580566] - The Division 12 APA task force 
recommendations. Empi[INVESTIGATOR_580567]. 1998; 5, 3 -25. 
9. Herbert MS, Afari N, Liu L, Heppner P, Rutledge T, Williams K et al. Telehealth Versus In-Person Acceptance and Commitment Therapy for Chronic Pai n: A Randomized Noninferiority Trial. J Pain. 
2017;18(2):200-211. DOI:10.1016/j.jpain.2016.10.014.  
10. Hughes LS, Clark J, Colclough JA, Dale E, McMillan D. Acceptance and Commitment Therapy (ACT) for 
Chronic Pain: A Systematic Review and Meta -Analyses. Clin J  Pain. 2017;33(6):552-568. 
DOI:10.1097/AJP.0000000000000425.  
11. Lin J, Sander L, Paganini S, Schlicker S, Ebert D, Berking M et al. Effectiveness and cost -effectiveness 
of a guided internet - and mobile-based depression intervention for individuals with chroni c back 
pain: protocol of a multi -centre randomised controlled trial. BMJ Open. 2017;7(12):e015226. 
DOI:10.1136/bmjopen -2016-015226. 
12. Scott W, Chilcot J, Guildford B, Daly -Eichenhardt A, McCracken LM. Feasibility randomized-
controlled trial of online Accepta nce and Commitment Therapy for patients with complex chronic 
pain in the [LOCATION_008]. Eur J Pain. DOI:10.1002/ejp.1236. 
13. Alev L, Fujikoshi S, Yoshikawa A, Enomoto H, Ishida M, Tsuji T et al. Duloxetine 60 mg for chronic low back pain: post hoc responder analysis of double- blind, placebo -controlled trials. J Pain Res. 
2017;10:1723-1731. DOI:10.2147/JPR.S138297.  
14. Du S, Hu L, Dong J, Xu G, Chen X, Jin S et al. Self- management program for chronic low back pain: A 
systematic review and meta-analysis. Patient Ed uc Couns. 2017;100(1):37-49. 
DOI:10.1016/j.pec.2016.07.029.  
 
BEST Trial Protocol v 7.0 66 9/1/[ADDRESS_763464] Rev. 2014;< Missing v olume number >(9):CD000963. DOI:10.1002/14651858.CD000963.pub3.  
16. Deyo RA, Von Korff M, Duhrkoop D. Opi[INVESTIGATOR_580568]. BMJ. 2015;350:g6380. DOI:10.1136/bmj.g6380.  
17. Barreto TW, Lin KW. Noninvasive Treatments for Low Back Pain. Am Fam Physician. 2017;96(5):324-327.  
18. Skelly AC, Chou R, Dettori JR, Turner JA, Friedly JL, Rundell SD, Ferguson AJR, et al. In Noninvasive Nonpharmacological Treatment for Chronic Pain: A Systematic Review. 2018; Rockville (MD).  
19. van Middelkoop M, Rubinstein SM, Kuijpers T, Verha gen AP, Ostelo R, Koes BW et al. A systematic 
review on the effectiveness of physical and rehabilitation interventions for chronic non-specific low back pain. Eur Spi[INVESTIGATOR_050] J. 2011;20(1):19-39. DOI:10.1007/s00586-010- 1518-3.  
20. Chou R, Subacute and chronic low back pain: Nonpharmacologic and pharmacologic treatment. UpToDate. Accessed 2021.  
21. Wenger HC, Cifu AS. Treatment of Low Back Pain. JAMA. 2017;318(8):743-744. DOI:10.1001/jama.2017.9386.  
22. Chou R, Deyo R, Friedly J, Skelly A, Hashimoto R, Weimer M et al. Nonphar macologic Therapi[INVESTIGATOR_580569]: A Systematic Review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2017;166(7):493-505. DOI:10.7326/M16-2459.  
23. The Interagency Pain Research Coordinating Committee. (2014). Federal Pain Research Strategy.  Retrieved from https://www.iprcc.nih.gov/sites/default/files/documents/FPRS_Research_Recommendations_Final_508C.pdf.  
24. Chou R, Deyo R, Friedly J, Skelly A, Hashimoto R, Weimer M, Brodt E, et al. In Noninvasive Treatments for Low Back Pain. 2016; Rockville (MD).  
25. McDonagh MS, Selph SS, Buckley DI, et al. Nonopi[INVESTIGATOR_580570] 
[Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Apr. (Comparative 
Effectiveness Review, No. 228.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK556277/. 
26. Moman RN, Dvorkin J, Pollard EM, Wanderman R, Murad MH, Warner DO et al. A Systematic Review and Meta -analysis of Unguided Electronic and Mobile Health Technologies for Chronic Pain-Is It 
Time to Start Prescribing Electronic Health Applications. Pain Med. 2019;20(11):2238-2255. DOI:10.1093/pm/pnz164.  
27. Vijan S, Manaker S, Qaseem A. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain. Ann Intern Med. 2017;167(11):835-836. DOI:10.7326/L17-0475.  
28. Wetherell JL, Afari N, Rutledge T, Sorrell JT, Stoddard JA, Petkus AJ et al. A randomized, controlled trial of acceptance and commitment therapy and cognitive -behavioral therapy for chronic pain. 
Pain. 2011;152(9):2098-2107. DOI:10.1016/j.pain .2011.05.016. 
29. Krebs EE, Lorenz KA, Bair MJ, Damush TM, Wu J, Sutherland JM et al. Development and initial validation of the PEG, a three -item scale assessing pain intensity and interference. J Gen Intern Med. 
2009;24(6):733-738. DOI:10.1007/s11606-009-0981-1.  
 
BEST Trial Protocol v 7.0 67 9/1/2023  30. Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB et al. Core outcome domains for 
chronic pain clinical trials: IMMPACT recommendations. Pain. 2003;106(3):337 -345. 
DOI:10.1016/j.pain.2003.08.001.  
31. Turk DC, Dworkin RH, Revicki D, Harding G, Burke LB, Cella D et al. Identifying important outcome 
domains for chronic pain clinical trials: an IMMPACT survey of people with pain. Pain. 2008;137(2):276-285. DOI:10.1016/j.pain.2007.09.002.  
32. Amtmann D, Cook KF, Jensen MP, Chen WH, Choi S, Revicki D et al. Development of a PROMIS item bank to measure pain interference. Pain. 2010;150(1):173-182. DOI:10.1016/j.pain.2010.04.025.  
33. Askew RL, Cook KF, Revicki DA, Cella D, Amtmann D. Evidence from diverse clinical populations supported clinical validity of PROMIS pain interference and pain behavior. J Clin Epi[INVESTIGATOR_5541]. 2016;73:103- 111. DOI:10.1016/j.jclinepi.2015.08.035.  
34. Chen CX, Kroenke K, Stump TE, Kean J, Carpenter JS, Krebs EE et al. Estimating minimally important 
differences for the PROMIS pain interferenc e scales: results from 3 randomized clinical trials. Pain. 
2018;159(4):775-782. DOI:10.1097/j.pain.0000000000001121.  
35. Kroenke K, Yu Z, Wu J, Kean J, Monahan PO. Operating characteristics of PROMIS four -item 
depression and anxiety scales in primary care patients with chronic pain. Pain Med. 
2014;15(11):1892-1901. DOI:10.1111/pme.[ZIP_CODE].  
36. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113(1 -2):9 -19. 
DOI:10.1016/j.pain.2004.09.012.  
37. Farrar JT, Young JP, LaMoreaux L, Wert h JL, Poole MR. Clinical importance of changes in chronic pain 
intensity measured on an 11 -point numerical pain rating scale. Pain. 2001;94(2):149-158. 
DOI:10.1016/S0304-3959(01)[ZIP_CODE]-9.  
38. Shellock R & D Services Inc. Screening form. ScreeningForm. Retrieved from http://www.mrisafety.com/ScreeningForm.html.  
39. Graven -Nielsen T, Kendall SA, Henriksson KG, Bengtsson M, Sörensen J, Johnson A et al. Ketamine 
reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain. 2000;85(3):483-4 91. DOI:10.1016/S0304-3959(99)[ZIP_CODE]-5.  
40. Price DD, Mao J, Frenk H, Mayer DJ. The N -methyl -D-aspartate receptor antagonist 
dextromethorphan selectively reduces temporal summation of second pain in man. Pain. 1994;59(2):165-174. DOI:10.1016/0304-3959(94)[ZIP_CODE]-8.  
41. Price DD, Staud R, Robinson ME, Mauderli AP, Cannon R, Vierck CJ. Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients. Pain. 2002;99(1 -2):49-59. 
DOI:10.1016/s0304-3959(02)[ZIP_CODE]-2.  
42. Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD. Abnormal sensitization and temporal summation of second pain (wind -up) in patients with fibromyalgia syndrome. Pain. 2001;91(1 -
2):165-175. DOI:10.1016/s0304-3959(00)[ZIP_CODE]-2.  
43. Petersen KK, Arendt -Nielsen L, Simonsen O, Wilder -Smith  O, Laursen MB. Presurgical assessment of 
temporal summation of pain predicts the development of chronic postoperative pain 12 months after total knee replacement. Pain. 2015;156(1):55-61. DOI:10.1016/j.pain.0000000000000022.  
 
BEST Trial Protocol v 7.0 68 9/1/[ADDRESS_763465]- thoracotomy pain intensity during the 
acute postoperative phase. J Pain. 2009;10(6):628-636. DOI:10.1016/j.jpain.2008.12.009.  
45. Locke D, Gibson W, Moss P, Munyard K, Mamotte C, Wright A. Analysis of meaningful conditioned 
pain modulation effect in a pain -free adult population. J Pain. 2014;15(11):1190-1198.   
46. Goodin BR, McGuire L, Allshouse M, et al. Associations between catastrophizing and endogenous 
pain -inhibitory processes: sex differences. J Pain. 2009;10(2):180-190.   
47. Oono Y, Nie H, Matos RL, Wang K, Arendt-Nielsen L. The inter - and intra -individual variance in 
descending pain modulation evoked by [CONTACT_580645] y men. Scand J Pain. 
2011;2(4):162-169.   
48. Nir RR, Granovsky Y, Yarnitsky D, Sprecher E, Granot M. A psychophysical study of endogenous analgesia: the role of the conditioning pain in the induction and magnitude of conditioned pain modulation. Eur J Pain. 2011;15(5):491- 497.   
49. Feliu-Soler A, Montesinos F, Gutiérrez -Martínez O, Scott W, McCracken LM, Luciano JV. Current 
status of acceptance and commitment therapy for chronic pain: a narrative review. J Pain Res. 2018;11:2145-2159. DOI:10.2147/JPR.S144631.  
50. Bothmer J, Broatch J, Hemmenway N, Moore A, Toussaint C, Breslin J, Veasley C, et al. Chronic Pain Assessment: Patient Perspectives. 2019; Retrieved from http://www.forgrace.org/grace -
content/uploads/2019/11/Grunenthal -Pain-Scale-FINAL -2-11.19.pdf  
51. McCracke n LM, Sato A, Taylor GJ. A trial of a brief group -based form of acceptance and commitment 
therapy (ACT) for chronic pain in general practice: pi[INVESTIGATOR_580571]. J Pain. 2013;14(11):1398-1406. DOI:10.1016/j.jpain.2013.06.011.  
52. Kioskli K, Scot t W, Winkley K, Godfrey E, McCracken LM. Online Acceptance and Commitment 
Therapy for People with Painful Diabetic Neuropathy in the [LOCATION_008]: A Single-Arm Feasibility Trial. Pain Med. 2020;21(11):2777-2788. DOI:10.1093/pm/pnaa110.  
53. Scott W, Guildford  BJ, Badenoch J, Driscoll E, Chilcot J, Norton S et al. Feasibility randomized-
controlled trial of online acceptance and commitment therapy for painful peripheral neuropathy in people living with HIV: The OPEN study. Eur J Pain. 2021;25(7):1493 -1507. DOI:10.1002/ejp.1762.  
54. Janevic M, Robinson -Lane SG, Murphy SL, Courser R, Pi[INVESTIGATOR_74182]. A Pi[INVESTIGATOR_613] a Chronic Pain Self-
Management Program Delivered by [CONTACT_580646]. Pain Med. [published online: March 29 , 2021]. DOI:10.1093/pm/pnaa468.  
55. Knoerl R, Smith EML, Barton DL, Williams DA, Holden JE, Krauss JC et al. Self -Guided Online Cognitive 
Behavioral Strategies for Chemotherapy -Induced Peripheral Neuropathy: A Multicenter, Pi[INVESTIGATOR_2268], 
Randomized, Wait-List Control led Trial. J Pain. 2018;19(4):382-394. 
DOI:10.1016/j.jpain.2017.11.009.  
56. Kratz AL, Alschuler KN, Williams DA, Ehde DM. Development and pi[INVESTIGATOR_97344] a web-based symptom management program for multiple sclerosis: My MS toolkit. Rehabil Psychol. 2021;66(2) :224-232. DOI:10.1037/rep0000375.  
 
BEST Trial Protocol v 7.0 69 9/1/[ADDRESS_763466] -Delivered Cognitive -Behavioral 
Therapy for Knee Osteoarthritis: A Randomized Pi[INVESTIGATOR_16116]. Am J Occup Ther. 
2018;72(5):7205205040p1-7205205040p9. DOI:10.5014/ajot.2018.027870.  
58. Williams DA, Kuper D, Segar M, Mohan N, Sheth M, Clauw DJ. Internet -enhanced management of 
fibromyalgia: a randomized controlled trial. Pain. 2010;151(3):694-702. DOI:10.1016/j.pain.2010.08.034.  
59. Agency for Healthcare Research and Quality. Systematic review update: Noninvasive 
nonpharmacologic treatments for chronic pain. Effective Health Care Program. Retrieved from: 
https://effectivehealthcare.ahrq.gov/products/noninvasive -nonpharm-pain-update/protocol. 
Published March 1, 2019.  
60. Croke LM. Low back Pain: American College of physicians PRACTICE guideline on Noninvasive 
treatments. American Family Physician. https://www.aafp.org/afp/2017/0915/p407.html. Published September 15, 2017. Accessed August 17, 2021.  
61. Atkinson, A. C. (2014). Selecting a Biased-Coin Design. Statistical Science. 2014; 29(1), 144 -163. 
DOI:10.1214/13-Sts449 
62. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31(1):103 -115.DOI:  10.2307/[ADDRESS_763467]. Minimization: a new method of assigning patients to treatment and control groups. Clin Pharmacol Ther. 1974;15(5):443-453. DOI:10.1002/cpt1974155443.  
64. Salama I, Ivanova A, Qaqish B. Efficient generation of constrained block allocation sequences. Stat Med. 2008;27(9):1421-1428. DOI:10.1002/sim.3014.  
65. Kosorok MR, Laber EB. Precision Medicine. Annu Rev Stat Appl. 2019;6:263 -286. 
DOI:10.1146/annurev-statistics -030718-105251.  
66. Butler EL, Laber EB, Davis SM, Kosorok MR. Incorporating Pat ient Preferences into Estimation of 
Optimal Individualized Treatment Rules. Biometrics. 2018;74(1):18 -26. DOI:10.1111/biom.[ZIP_CODE].  
67. Butler EL. Using patient preferences to estimate optimal treatment strategies for competing 
outcomes. University of North Caro lina at Chapel Hill, Chapel Hill. 2016; Retrieved from 
https://www.proquest.com/docview/[PHONE_12047]?pq-origsite=gscholar&fromopenview=true  
68. Kosorok MR, & Moodie EEM. Adaptive Treatment Strategies in Practice Planning Trials and Analyzing 
Data for Personaliz ed Medicine Preface. Adaptive Treatment Strategies in Practice: Planning Trials 
and Analyzing Data for Personalized Medicine. 2016; Xv -+.  
69. Chakraborty B, Laber EB, Zhao Y. Inference for optimal dynamic treatment regimes using an adaptive m -out-of-n bootstr ap scheme. Biometrics. 2013;69(3):714-723. DOI:10.1111/biom.[ZIP_CODE].  
  
 
BEST Trial Protocol v 7.0 70 9/1/2023  16. SURVEY QUESTIONNAIRES   
 
Abbreviated Pain Somatization  
Current Opi[INVESTIGATOR_580572]-PA scale  
NHANES Food Frequency*  
GAD -2  
GSS-8  
HEAL Resilience  Hip/Knee replacement  
Low-Back Pain Duration  
Low-Back Pain Frequency  
Low-Back Pain Specific Pain Intensity  
Michigan Body Map  
Oswestry Disability Index  
Pain Catastrophizing Scale SF 6  
Pain, Enjoyment of Life, and General Activity (PEG)  
PainDETECT  
Patient Global Impressions Scale (PGIC)  
Patient Preference for Outcome  
Patient Preference for Treatment  
Patient Satisfaction with Outcomes  
PHQ-2  
PROMIS 29+2 / PROPr  
Radicular Pain  
Sleep duration  Social Determinants of Health  
SSI (symptom severity index)  
StartBack Tool  
TAPS 1  
Treatment Categorization  
Widespread Pain Inventory   
 
*Will be pi[INVESTIGATOR_580573] v 7.0 71 9/1/2023   
17. APPENDIX A:  SCHEDULE OF ACTIVITI ES 
 
BEST Trial Protocol v 7.0 72 9/1/[ADDRESS_763468] Run-In Screening
Visit 0 (Baseline)
Visit 0 (Baseline optional day 2)
Week1
Week2
Week3
Week4
Week5
Phone Call1 (week 6)
Week7
Week8
Week9
Week10
Week11
Visit 1 (Week 12)
Visit 1 (Week 12 optional day 2)
Week 13
Week 14 
Week 15 
Week 16 
Week 17 
Phone Call 2 (week 18)
Week 19 
Week 20 
Week 21 
Week 22 
Week 23 
Visit 2 (Week 24)
Visit 2 (Week 24 optional day 2)
Phone Call 3: Safety follow-up (week 28)
Phone Call 4: Observational follow-up for 
subset (week 36)**
EMR Review/ Interview/ Pre-screen eligibility X
Low-Back Pain Duration Q'naire X
Low-Back Pain Frequency Q'naire X
Low-Back Pain Intensity X X X X X X X
Low-Back Pain Severity Q'naire X X X X X
PEG X X X X X X X
Eligibility Assessment QuestionsX X X X X X X
Demographics X X
Informed Consent X
Contact [CONTACT_130052] X X
Schedule study visits X X X X
Review of study informational materials X X X
Introduction/ Onboarding to patient website X
Introduction/ Onboarding to Run-In X
Daily Pain Questions X X
Post run-in assessment X
Sleep duration Question X X X X
Abbreviated Pain Somatization X X X X
Radicular Pain Questions X X X X
FABQ-PA scale X X X X
GSS-8 X
Pain Catastrophizing Scale SF 6 X X X X
PHQ-2 X X X X
GAD-2 X X X X
TAPS 1 X X X X
Social Determinants of Health X
Perceived Discrimination X
HEAL Positive Outlook X X X X
PROMIS 29+2 / PROPr X X X X
Treatment Categorization Q’naire X X X X
StartBack Tool X
SSI (symptom severity index) X
Widespread Pain Inventory X X X X
Current Opi[INVESTIGATOR_5536] X X X X
ODI X
Satisfaction overall ranking X X
Satisfaction with treatment X XX
COVID vaccination status question X X XX
COVID previous diagnosis question X X XX
Michigan Body Map X
PainDETECT X
Patient Preference Tool X X X X
Food Frequency Questionnaire X
Physical Assessment X X X
Randomization to 1st period Intervention X
Blood collection X X X
Stool collection Xx*
Biomechanical assessment (light)Xx* Xx* Xx*
Basic Spi[INVESTIGATOR_580574]*
Activity monitoring (deep)Xx*
Biomechanical assessment (deep)Xx* Xx* Xx*
Advanced Spi[INVESTIGATOR_580574]*
Brain MRIXx* Xx* Xx*
Quantitative Sensory TestingXx* Xx* Xx*
PGIC X X X X X
Intervention tolerance assessment/ Adverse Events X X X X
End-of-study safety assessment X
Randomization to 2nd period Intervention X
Scheduling/Introduction/Onboarding to 2nd period Activities XSchedule of Activities: National Institute of Arthritis and Musculoskeletal and Skin Diseases, (NIAMS) - BACPAC - 21-1972, The BEST Trial: Biomarkers for Evaluating, Spi[INVESTIGATOR_580503] (Pro00057948)***
 
BEST Trial Protocol v 7.0 73 9/1/2023   
Schedule of Activities: The BEST Trial: Biomarkers for Evaluating, Spi[INVESTIGATOR_580503] (Pro00057948)***  
 
* If not completed on day 1 of the visit           
** Participants who are enrolled early enough to complete the 36 -week assessments       
*** Refer to Manual of Procedures for Visit Windows  ACT intervention-specific contact [CONTACT_360222] X X X X
Duloxetine intervention-specific contact [CONTACT_360222] X X
EBEM intervention-specific contact [CONTACT_360222] X X X X X X X X X X X X
ESC intervention-specific contact [CONTACT_580647] (maintenance subset) Intervention-specific contact [CONTACT_360222]